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1 Zusammenfassung/Summary  
Die Embryonalentwicklung stellt einen hochkomplizierten, multifaktoriellen Prozess dar. 
Hierbei müssen Spezifizierung, Musterbildung und Differenzierung von Zellen und Geweben 
zeitlich und räumlich genauestens kontrolliert werden. Dies impliziert die Regulierung einer 
Vielzahl unterschiedlicher Gene. Nur eine kleine Anzahl von Transkriptionsfaktoren scheint 
jedoch für diese Regulierung verantwortlich zu sein. 
Oct4, Sox2 und Nanog bilden ein Netzwerk, das eine wichtige Rolle bei der 
Pluripotenzerhaltung und der zeitlichen Regulierung der Differenzierung spielt. Die zentrale 
Rolle von Oct4 in Säugetieren wurde durch jüngste Forschungsergebnisse unterstrichen, die 
zeigten, dass Oct4 entscheidend bei der Reprogrammierung somatischer Zellen beteiligt ist. 
Dennoch ist bislang wenig über die molekularen Regulationsmechanismen dieses 
Transkriptionsfaktors während der Normogenese bekannt.  
Beim Xenopus laevis (Krallenfrosch) entwickeln sich die Embryonen extrauterin. Seine 
Embryonalentwicklung ist genauestens studiert und Techniken wie embryonale RNA- und 
DNA-Injektionen sind gut etabliert. Daher stellt Xenopus laevis einen idealen 
Modellorganismus für die Untersuchung von Oct4 homologen Proteinen in der frühen 
Embryonalentwicklung dar. 
Im Xenopus laevis sind drei Oct4 Paraloge – Oct25, Oct60 und Oct91 – bekannt, welche 
eine ähnliche Größe besitzen und hohe Sequenzhomologien mit dem Säugetier Oct4  
aufweisen. Es gibt starke Hinweise, dass Xenopus Oct Proteine ähnliche Funktionen wie 
Oct4 innehaben.  
Um die Funktion der Oct Proteine genauer zu studieren, habe ich dominant aktivierende 
(VP16-Oct60), dominant reprimierende (EnR-Oct60) und hormoninduzierbare (GR-Oct60) 
Transkriptionsfaktor-Varianten für alle drei Xenopus Oct Proteine generiert. Die 
Proteinexpression wurde sowohl in vitro, als auch in vivo verifiziert.  
Verglichen mit anderen Xenopus Oct Proteinen zeigt Oct60 ein einzigartiges 
Expressionsmuster: Oct60 wird maternal transkribiert und seine RNA ist in reifen Oocyten 
nachweisbar. Die Expression nimmt während dem Gastrulastadium, wenn die Expression 
der anderen Xenopus POU Proteine beginnt, wieder ab.  Somit gehört Oct60 zu den ersten 
Genen die exprimiert werden. Daher haben wir uns entschlossen uns vorerst auf die 
Untersuchung von Oct60 zu konzentrieren. 
Die transaktivierenden Eigenschaften der Oct60 Funktionsgewinn- („gain of function“) 
Proteine wurden in vivo durch einen Luciferase-Assay mit zwei unterschiedlichen Oct4 
Reporterkonstrukten untersucht. Hierbei zeigte sich eine starke Aktivierung beider Reporter 
durch Oct60 und VP16-Oct60 sowie eine Repression durch EnR-Oct60.  
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Durch die Injektion von Oct60 und seinen „gain of function“ Varianten konnten wir mehrere, 
verschiedene Körperregionen betreffende, phänotypische Veränderungen beobachten. 
Neben einer schwerwiegenden Behinderung der Differenzierung im Bereich des Kopfes, 
hervorgerufen durch VP16-Oct60 und Oct60 Überexpression, konnten wir eine starke 
Hyperpigmentierung in EnR-Oct60 und Oct60 injizierten Embryonen beobachten. Weiterhin 
zeigten EnR-Oct60 injizierte Embryonen hyperpigmentierte Auswüchse im Bereich der 
Flanke. Alle injizierten Embryonen wiesen verkürzte Körperachsen mit einer spezifischen 
Krümmung abhängig von der injizierten RNA auf. Um die zugrunde liegenden molekularen 
Mechanismen dieser phänotypischen Veränderungen zu analysieren führten wir in situ 
Hybridisierungen durch. Diese zeigten, dass alle untersuchten Konstrukte die Bildung von 
neuroektodermalem Gewebe fördern und gleichzeitigen die Mesodermbildung hemmen. 
Diese Ergebnisse weisen darauf hin, dass Oct60 die Induktion und Spezifikation der 
Keimblattbildung beeinflusst. Durch die Klonierung und Charakterisierung verschiedener 
neomorpher Proteinvarianten ist es uns gelungen wichtige Werkzeuge für die weitere 
Untersuchung von Oct4 Homologen im Xenopus laevis zu entwickeln. 
 
 
Summary 
Embryonic development represents a sophisticated multistep process. Hereby, specification, 
patterning and differentiation of cells and tissue need to be extremely well regulated in a 
temporo-spatial manner. This is based on repression and activation of a vast number of cell-
type specific genes, but only a small number of transcription factors seem to be responsible 
for their regulation.  
The transcription factor network of Oct4, Sox2 and Nanog are thought to play an essential 
role in the maintenance of pluripotency and in timing the onset of differentiation. The 
importance of mouse Oct4 in the regulation of pluripotency is underscored by recent findings 
providing evidence that Oct4 is essential for reprogramming somatic cells. Nevertheless, little 
is known on the molecular function of this transcription factor during normogenesis. Given 
the extra-uterine development of the embryos, the well-studied early development and the 
established manipulation methods like injection of RNA or DNA, Xenopus leavis offers an 
ideal model organism to study the role of Oct4 homologs in early development. 
In Xenopus laevis three Oct4 paralogs – Oct25, Oct60 and Oct91 – are known, which are 
similar in size and have a high sequence homology compared to mammalian Oct4. There are 
strong evidences that Xenopus Oct proteins and mammalian Oct4 share similar functions. 
To gain further insights into the function of Oct proteins I generated dominant activating- 
(VP16-Oct60), dominant repressing- (EnR-Oct60) and hormone inducible (GR-Oct60) 
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transcription factor variants for all three Xenopus Oct proteins. Protein expression was 
verified in vitro as well as in vivo.  
Oct60 shows a unique expression pattern among Xenopus Oct proteins: Oct60 is maternally 
transcribed and its RNA is detectable in mature oocytes. Expression is downregulated in the 
gastrula, when the expression of other Xenopus POU proteins begins. Therefore, it is one of 
the earliest genes to be expressed. I decided to concentrate first efforts on Oct60.  
The transactivating functions of the Oct60 G.o.F. variants were tested in a luciferase assay 
on two different Oct4 reporter constructs in vivo. Oct60 and VP16-Oct60 acted as strong 
activators whereas EnR-Oct60 repressed both reporter constructs. 
By overexpression of Oct60 and its G.o.F. variants, several phenotypes were observed that 
affected distinct parts of the body. Beside impaired head differentiation, observed by 
overexpression of VP16-Oct60 and Oct60, a strong hyperpigmentation was observed by 
injection of EnR-Oct60 and Oct60. Additionally, EnR-Oct60 injected embryos showed 
hyperpigmented outgrowths in the trunk region. All injected embryos possessed a shortened 
body axis that was specifically curved depending on the injected mRNA.  
In situ hybridizations were performed to investigate the molecular mechanism of the 
observed phenotypic changes. Experiments revealed that all examined constructs promote 
neuroectodermal fate while repressing mesoderm formation.  
These results indicate that Oct60 plays an important role in the induction and specification of 
germ layer formation. By cloning and testing these different G.o.F. variants I accomplished to 
obtain important tools for further dissecting the molecular function of Oct4 homologs in 
Xenopus embryos. 
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2 Introduction  
2.1 Stem cells 
Embryogenesis is the fundamental process of differentiation of all tissues from a unicellular 
zygote. From a single totipotent cell distinct stem cells emerge that will form the three germ layers 
– ectoderm, mesoderm and endoderm and will later differentiate to over 200 unique cell types 
(Loebel, Watson et al. 2003; Boyer, Lee et al. 2005). All these events need to be extremely well 
regulated in the temporo-spatial context of the developing organism.  
 
Stem cells possess two unique characteristics: their self-renewal and differentiation potential. 
Therefore, they are different from progenitor cells, which can differentiate into mature cell types 
but are incapable of self-renewing, or somatic cells, which are capable of proliferating but unable 
to differentiate. 
According to their differential potential, stem cells are being subdivided into totipotent, pluripotent 
and multipotent cells although the boundaries between them are constantly in a state of flux. 
Totipotent cells hold the indefinite feature of differentiating into all adult and embryonic tissues, 
including extra-embryonic tissues such as trophectoderm. Pluripotent stem cells are capable of 
differentiating into the derivatives of the three germ layers (ectoderm, mesoderm and endoderm) 
and germ cells. However, they cannot differentiate into certain cell types especially extra- 
embryonic tissues such as trophectoderm and are therefore not able to form a viable organism. 
Multipotent stem cells have an even lower potential and can only differentiate into a limited 
number of cell types.  
The earliest stem cells in ontogeny - the zygote and to some extend early blastomeres - are 
totipotent. They give rise to somatic stem/progenitor cells and primitive germ line stem cells. At 
about the neurula stage, tissue and organ specific stem cells emerge. Little is known about the 
stages of somatic stem cells between the blastocyst stage and the neurula stage (Weissman 
1999; Surani, Hayashi et al. 2007; Guo, Huss et al. 2010). 
 
This classification might create the misimpression, that totipotency, pluripotency and multipotency 
are homogenous and stable states. Contrary to this assumption, basic research has provided 
more and more data suggesting that they are time dependent characteristics that only represent 
a snap shot in development.  Therefore, there is possibly not one kind of pluripotent cell but more 
a cell that is passing a pluripotent state with different features at different examined points in time. 
Pluripotent stem cells might be more heterogeneous in nature then they are most often thought to 
be and more than one ‘state of pluripotency’ may exist. (Skottman, Mikkola et al. 2005; Kalmar, 
Lim et al. 2009; Cherry and Daley 2010) 
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2.2 Stem cells in medicine 
In medicine, great hopes are being pinned on tissue regeneration using stem cells. Stem cell 
therapies are promising solutions for currently unmet medical needs. They would open new 
prospects for the replacement of damaged or aged cells for example in patients with 
degenerative illnesses like age-related functional defects, haematopoetic and immune system 
disorders, heart failure, chronic liver injuries, Alzheimer, diabetes type I, multiple sclerosis, 
Parkinson’s disease as well as aggressive or recurrent cancer. Additionally they could be useful 
as gene ferries for gene therapy (Weissman 2000; Lian, Chow et al. 2010).  
Numerous recent investigations carried out with ex vivo expanded and/or differentiated 
embryonic -, fetal-, and umbilical cord stem cell-derived fully functional progeny as well as adult 
stem cells have provided accumulating evidence supporting their potential use for the treatment 
of numerous disorders (Barrilleaux, Phinney et al. 2006; Bryder, Rossi et al. 2006; Mimeault and 
Batra 2006; Behfar, Perez-Terzic et al. 2007; Ringden 2007; van Vliet, Sluijter et al. 2007; Wu, 
Boyd et al. 2007) 
    
In 1997 transplantation experiments have shown that neural precursor cells generated in vitro 
can participate in the development of embryonic rat brain. After the transplantation of glial 
precursor cells into the ventricle of myelin-deficient rat brains, the formation of new myelin sheets 
could be observed in various brain regions (Brustle, Spiro et al. 1997). However, even more than 
10 years later, there are only very few fields in medicine – e.g. cardiac infarction - where stem 
cells are used for clinic therapies. Even there, the results are not satisfying.  Implementation in 
clinical settings requires extensive safety studies and a solution to immunogenic issues in 
particular. In the therapy of Parkinson’s disease the use of stem cells also did not proof to be 
successful. Precursors of dopaminergic neurons in cultured mesencephalic cells obtained from 
human embryos, aborted 7–8 weeks after conception, were transplanted to Parkinson’s disease 
patients. Some of the implanted cells survived and differentiated. Improvement rates were low 
and in 15% of the patients, spontaneous dyskinesias developed as a disabling complication 
(Freed, Greene et al. 2001).  
Taken together, stem cells and their progeny constitute cells with an enormous therapeutic 
potential to treat and even cure diverse genetic and degenerative disorders, which are currently 
incurable with other types of treatments. For a fundamental understanding of human 
development and to achieve the goal of clinical application, it is essential to understand the 
molecular mechanisms underlying the pluripotency of ES cells. Especially for clinical application, 
it is important to make better use of the distinctions between the pluripotent and differentiated 
states. ES cells need to be differentiated efficiently into a specific lineage and undifferentiated ES 
cells have to be eliminated from the differentiated cells. Further improvement might be achieved 
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by reprogramming adult cells. These cells could enable the production of patient-specific cell 
types, which are fully immune-compatible with the original donor. Furthermore, induced stem 
cells from patients suffering from diverse diseases could be differentiated into the cell type 
targeted by the disease and thereby providing in vitro models for studying pathogenesis as well 
as pharmacological and toxicological testing (Arsenijevic 2005; Teo and Vallier 2010). 
 
 
2.3 Molecular mechanisms involved in the maintenance of 
pluripotency 
Embryonic development is based on repression and activation of a vast number of cell-type 
specific genes but only a small number of transcription factors are thought to be responsible for 
their regulation. One property of ES cells is their continuous self-renewal, which requires that the 
unique transcriptional profile of the pluripotent state is maintained. Both transcriptional regulation 
and epigenetic regulation play pivotal roles in maintaining the existing transcriptional profile and 
controlling the plasticity of the transcriptional profile (Surani, Hayashi et al. 2007). Additionally, 
micro-RNAs (miRNAs) are emerging as regulators of pluripotency (Chen and Daley 2008). 
 
 
2.3.1 Transcriptional regulation of pluripotency 
The existence of pluripotency factors has been hypothesized for a long time. To test this idea, 
some early studies compared global transcriptional profiles of ES cells and their differentiated 
Figure 1: Genetic and epigenetic 
regulation of pluripotency during mouse 
development. 
Oct4, Sox2 and Nanog are being inherited 
maternally and are expressed within the pluripotent 
tissue  (indicated in red).  
Early germ cells exhibit epigenetic and 
transcriptional states that are associated with 
pluripotency. The figure depicts the main epigenetic 
changes occurring during the critical stages of 
development. The figure was modified from Surani, 
Hayashi et al. (2007).  
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derivatives (Ivanova, Dimos et al. 2002; Ramalho-Santos, Yoon et al. 2002; Sato, Sanjuan et al. 
2003). Interestingly, the results of these studies varied significantly and revealed an overlap of 
only about 1,5% (Evsikov and Solter 2003; Fortunel, Otu et al. 2003). Nevertheless, a few 
individual genes were successfully identified as critical pluripotency factors. 
The two homeodomain transcription factors Oct4 and Nanog were the first proteins identified as 
essential for both early embryonic development and pluripotency maintenance in ES cells 
(Nichols, Zevnik et al. 1998; Chambers, Colby et al. 2003).  
Another transcription factor that is thought to be involved in the regulation of pluripotency is Sox2. 
It belongs to the Sox (Sry-related HMG box-containing) gene family and is expressed in 
preimplantation embryos and in ES cells in a similar manner as Oct4 (Yuan, Corbi et al. 1995; 
Collignon, Sockanathan et al. 1996). Later in development, Sox2 is again coexpressed with Oct4 
in postmigratory primordial germ cells (Collignon, Sockanathan et al. 1996).  Sox2 is also 
expressed in other stem cells and precursor cells during development, including neural stem 
cells. Sox2-null mutant embryos cannot give rise to embryonic or trophectoderm lineages and are 
therefore not viable (Yuan, Corbi et al. 1995; Botquin, Hess et al. 1998).  
Oct4, Nanog and Sox2 share a substantial fraction of their target genes. Interestingly, these three 
factors control each others transcription in a regulatory circuit. Many targets of Oct4, Sox2 and 
Nanog encode key transcription factors for differentiation and development, and are 
transcriptionally inactive in ES cells. Oct4, Sox2 and Nanog also control genes that are 
transcriptional active in ES cells and thought to be involved in the maintenance of pluripotency. 
These three factors are therefore involved in blocking differentiation and maintaining the 
pluripotent state (Boyer, Lee et al. 2005; Loh, Wu et al. 2006). It should be noted, however, that 
the phenotypes of Oct4, Nanog and Sox2 knockout mice are not identical, which indicates also 
non-redundant functions (reviewed by (Boiani and Scholer 2005)).  
In addition to Oct4, Sox2 and Nanog, other factors required for pluripotency have been identified, 
including Sall4, Dax1, Essrb, Tbx3, Tcl1, Rif1, Nac1 and Zfp281 (Loh, Wu et al. 2006; Wang, Rao 
et al. 2006). 
Sall4, a member of the spalt-like protein family, interacts with Nanog and co-occupies Nanog and 
Sall4 enhancer regions. Thus, Sall4 regulates Nanog expression as well as the expression of ES 
cell-specific genes. Sall4 also regulates Oct4 expression by binding to the Oct4 promoter (Wu, 
Chen et al. 2006; Zhang, Tam et al. 2006). Essrb and Rif1 are primary targets of both Oct4 and 
Nanog (Loh, Wu et al. 2006). Starting with Nanog interacting proteins, a complicated 
transcriptional regulatory network in mouse ES cells has been constructed with Oct4 and Nanog 
placed in key positions and many of the genes encoding proteins in the interaction network are 
targets of Nanog and/or Oct4 (Wang, Rao et al. 2006). 
The importance of the Oct4 and Sox2 is underscored by recently published results of the groups 
of Thompson (Wisconsin, USA) and Yamanka (Kyoto, Japan). Both groups independently 
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accomplished to reprogram somatic cells to cells that behave like embryonic stem cells. Oct4, 
Sox2, c-Myc and Klf4 together can reprogram mouse embryonic and adult fibroblast cells to a 
pluripotent state (Takahashi and Yamanaka 2006; Okita, Ichisaka et al. 2007; Wernig, Meissner 
et al. 2007). These same four factors have also been proven capable of reprogramming human 
dermal fibroblasts (Takahashi, Tanabe et al. 2007). The group of Thompson showed that Oct4, 
Sox2, Nanog and Lin28 were sufficient to establish pluripotent cells from human somatic cells 
(Yu, Vodyanik et al. 2007). The induced pluripotent stem cells proliferate indefinitely in culture 
and differentiate into all tissues that are necessary to generate a live mouse. Though the proteins 
that were upregulated for reprogramming differed between both groups (Oct4, Sox2, Klf4 and c-
Myc used by the group of Yamanaka in contrast to Oct4, Sox2, Nanog and Lin28 used by the 
group of Thompson), both found out that two factors are essential: Sox2 and Oct4 (Takahashi, 
Tanabe et al. 2007; Yu, Vodyanik et al. 2007). These data suggest that Oct4 might be one of the 
key regulators to maintain and even induce stem cell pluripotency.  
 
2.3.2 Epigenetic regulation of pluripotency 
One feature of stem cells is their degree of self-renewal by which they can maintain the 
undifferentiated state through multiple cell divisions. But how is this undifferentiated state 
maintained, based on the fact that all cells of one organism posses the identical genome? The 
underlying principle of this cellular memory is most likely of epigenetic nature.  
Conrad Waddington coined the term epigenetics, when he defined it 1942 as “the branch of 
biology, which studies the causal interactions between genes and their products, which bring the 
phenotype into being” (Waddington 1942). In 1957, he published the epigenetic landscape 
(Waddington 1957). It describes the differentiating cell as a marble rolling along a hilly landscape. 
At each branches, the marble can choose between two ways. Thereby, it will have made several 
binary choices until it reaches the bottom of the landscape (for review see (Slack 2002)).  
 
 
 
Figure 2:  The epigenetic landscape  
(Figure taken from Waddington 1957) 
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From a more modern point of view the term 'epigenetics' describes heritable changes in genome 
function that are not due to changes in the nucleotide sequence of the DNA. Chromatin is 
subjected to various forms of epigenetic regulation that influence the transcriptional activity. This 
process includes chromatin remodeling, histone modifications, histone variants and DNA 
methylation. In general, trimethylation of lysine 9 and lysine 27 of histone 3 (H3K9 and H3K27) 
correlate with inactive regions of chromatin, whereas H3K4 trimethylation, and acetylation of H3 
and H4 are associated with active transcription, and DNA methylation generally represses gene 
expression (Jenuwein and Allis 2001; Lachner and Jenuwein 2002; Santos and Dean 2004; 
Kouzarides 2007). To maintain pluripotency in ES cells, genes whose upregulation leads to 
differentiation should be inactive whereas pluripotency factors should be expressed. Polycomb 
group proteins (PcG) play important roles in silencing these developmental regulators. The PcG 
proteins function in two distinct Polycomb Repressive Complexes, PRC1 and PRC2. Genome-
wide binding site analyses have been carried out for PRC1 and PRC2 in mouse ES cells and for 
PRC2 in human ES cells (Boyer, Plath et al. 2006; Lee, Jenner et al. 2006). The genes regulated 
by the PcG proteins are co-occupied by nucleosomes with trimethylated H3K27. These genes are 
transcriptionally repressed in ES cells and are preferentially activated when differentiation is 
induced. Many of these genes encode transcription factors with important roles in development. 
Interestingly, the pluripotency factors Oct4, Sox2 and Nanog co-occupy a significant fraction of 
the PcG protein regulated genes (Boyer, Plath et al. 2006; Lee, Jenner et al. 2006). These data 
suggest that the PcG proteins may facilitate pluripotency maintenance by suppressing 
developmental pathways. 
 
Beyond the specific regulations of development-related genes, ES cells exhibit unique chromatin 
features. Chromatin proteins in ES cells are hyperdynamic and bind loosely to chromatin. Upon 
differentiation, the hyperdynamic proteins tend to be immobilized on chromatin. Fewer 
heterochromatin foci are detected in ES cell nuclei and they seem to be more diffuse than those 
in differentiated cells (Meshorer and Misteli 2006). 
Hyperdynamic binding of structural chromatin proteins seems to be a functionally important 
hallmark of pluripotent ES cells. This feature appears to contribute to the maintenance of 
plasticity in undifferentiated ES cells and to the establishment of higher-order chromatin structure. 
Additionally “bivalent domains” – containing both the histone H3K4 as well as the histone H3K27 
trimethylation mark – were described in mouse ES cells (Bernstein, Mikkelsen et al. 2006). These 
“bivalent domains” are thought to keep cell-type specific genes repressed while keeping them 
poised for activation during differentiation. It was found that ES cell chromatin is enriched in 
active marks such as methylation H3K4 and acetylation of H3 and H4 whereas marks that are 
associated with repression of gene expression are diminished. Differentiation is associated with 
decrease in H3K4 trimethylation as well as an increase in H3K9 methylation and therefore 
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represents a transcriptionally less-permissive chromatin state (Lee, Hart et al. 2004; Meshorer, 
Yellajoshula et al. 2006).   
The highly dynamic and transcriptionally permissive chromatin environment in ES cells may 
facilitate rapid transcriptional profile alternations upon differentiation and allow various 
transcriptional profiles to be established. 
 
Pluripotency factors and epigenetic control seem to engage in cross talk with one another in 
order to maintain pluripotency.  It has been reported that Oct4, Sox2 and Nanog regulate genes 
that encode components of chromatin remodeling and histone modifying complexes, such as 
SMARCAD1, MYS3 and SET (Boyer, Lee et al. 2005). Pluripotency factors also interact with 
histone modifying enzymes and chromatin remodeling complexes. Nanog and Oct4 interact with 
the histone deacetylase NuRD (P66b and HDAC2), polycomb group (YY1, Rnf2 and Rybp) and 
SWI/SNF chromatin remodeling (BAF155) complexes (Wang, Rao et al. 2006). Additionally, the 
genes of pluripotency factors are subjected to epigenetic regulation. One example for the 
epigenetic regulation of pluripotency factors are the histone demethylases Jmjd1a and Jmjd2c, 
which are positively regulated by Oct4. By demethylating H3K9Me2 at the promoters Jmjd1a 
positively regulates pluripotency-associated genes, such as Tcl1, Tcfcf2l1 and Zfp57 (Loh, Zhang 
et al. 2007). Additionally, Jmjd2c positively regulates Nanog expression by removing H3K9 
trimethylation marks at the Nanog promoter. Depletion of Jmjd1a or Jmjd2c results in ES cell 
differentiation (Loh, Wu et al. 2006; Loh, Zhang et al. 2007). 
 
 
2.4 Oct-proteins 
Oct proteins are transcription factors that belong to the family of POU proteins. The acronym 
POU derives from the names of three mammalian transcription factors: 
• pituitary-specific Pit-1  
• octamer-binding proteins Oct-1 and Oct-2  
• neural Unc-86 from Caenorhabditis elegans.  
All Oct proteins contain a DNA binding POU domain that binds to the octamer motif ATGCAAAT, 
which was first found in the promoter of immunoglobulin genes. This binding sequence is found in 
the promoters and enhancers of many ubiquitously expressed and cell specific genes (Boheler 
2005). The POU domain consists of two highly conserved subdomains – a “POU specific domain” 
(POUs) and a C-terminal “POU homeodomain” (POUHD) that are joined by a flexible linker 
structure (Herr, Sturm et al. 1988; Herr and Cleary 1995) (Klemm, Rould et al. 1994). 
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The mammalian genome contains typically three Oct proteins: 
• Oct1: present in all eukaryotic cells 
• Oct2: present in cells of the immune and nervous system  
• Oct4: expressed in germ cells, totipotent and pluripotent cells during embryonic         
development 
 
 
2.5 The role of Oct4 in mouse early development 
2.5.1 Protein structure of Oct4 
Oct4, also known as Oct3, is a mammalian transcription factor expressed by early embryonic 
cells and germ cells. It belongs to the group of POU V transcription factors. The protein consists 
of 325 amino acids (Scholer, Dressler et al. 1990) (Rosner, Vigano et al. 1990). The 160 amino-
acid-long binding domain can be subdivided into the POUS domain, measuring 75-amino-acids 
and the 60-amino-acid long carboxy-terminal POUHD domain that are joined by a flexible linker 
region (Scholer 1991; Verrijzer and Van der Vliet 1993; Herr and Cleary 1995). The amino acid 
sequence of human OCT4 is 87% identical to that of the mouse, and the genomic organization, 
with regard to intron–exon boundaries is the same (Takeda, Seino et al. 1992; Abdel-Rahman, 
Fiddler et al. 1995). 
 
2.5.2 Expression profile of Oct4 
The gene POU5F1 encodes the Oct4 protein. The Oct4 gene has been found only in mammalian 
species. The gene maps to human chromosome 6 in a region homologous to mouse 
chromosome 17 (Takeda, Seino et al. 1992).  
C$stal Structure of a POU Domain-DNA Complex 
Figure 2. Overview of the POU Domain-DNA Complex 
(Top) Stereo view, with ribbons drawn through the Ca’s of the protein domains and through the phosphate backbone of the DNA strands. The 
POU homeodomain is red, and the POU-specfflc domain is yellow. The DNA is blue. with the octamer sequence highlighted in light blue. This 
figure was generated with Insight II software (Siosym Technologies). 
(Sottom) Sketch of the complex in a similar orientation. Cylinders Indicate the position of the a helices, and the dotted line is used to emphasize 
that these domains are covalently connected (even though the linker is flexible and cannot be traced in the electron density maps). 
comparing the crystal structure of the POU-specific com- 
plex with one-half of the X repr ssor complex shows that 
these proteins do bind DNA in a very similar manner (Fig- 
ure 9A) and that specific DNA contacts are conserved. 
Each protein has a glutamine at the start of helix 2 and 
a glutamine at the start of helix 3, and these make precisely 
analogous base and phosphate contacts in the POU com- 
plex and in the repressor complexes. Remarkably, even 
the extended hydrogen bonding network that involves Arg- 
20 and Glu-51 in 013-l is present in the 434 complexes. 
These similarities seem especially striking when we con- 
sider the vast evolutionary separation between these pro- 
teins and when we note that Ott-I has six additional resi- 
dues in the middle of the HTH unit. 
Structure and DNA Contacts 
of the POU Homeodomaln 
The overall structure and docking of the POU homeodo- 
main are similar to those observed in other homeodomain- 
DNA complexes (Kissinger et al., 1990; Otting et al., 1990; 
Figure 3: Binding of the POU homedomain 
and the POU specific domain to the octamer 
motif.  
POUS domains bind to the first (ATGCAAAT), POUHD 
domains to the second half (ATGCAAAT) of the octamer 
motif. The figure was modified from Klemm, Rould et al. 
(1994).  
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The expression of the Oct4 gene is regulated by two enhancers – a distal and a proximal 
enhancer - linked to a single promoter (Nordhoff, Hubner et al. 2001). The distal enhancer region 
contributes to Oct expression in preimplantation embryos, ES cells, and embryonic germ cell, 
whereas the proximal enhancer regulates expression stage-specific and is active in the epiblast 
of mouse embryos (Yeom, Fuhrmann et al. 1996; Ovitt and Scholer 1998; Gidekel and Bergman 
2002). Downregulation of Oct4 appears to be tightly controlled at several levels (Boheler 2005).  
Experiments indicate that epigenetic changes are involved in the regulation of Oct4. Analysis of 
the DNA methylation status of mouse Oct4 gene upstream region revealed that the Oct4 
enhancer/promoter region is DNA hypomethylated, while the corresponding nucleosomes are 
hyperacetylated in ES cells compared to trophoblast stem cells. Furthermore, in vitro methylation 
suppresses Oct4 enhancer/promoter activity (Hattori, Nishino et al. 2004). In vivo, repression of 
the Oct4 gene locus is associated with increased DNA methylation and changes in chromatin 
structure in the regulatory region (Ben-Shushan, Pikarsky et al. 1993). 
 
Oct4 mRNA and protein are detectable in unfertilized oocytes, and the protein is localized to the 
pronuclei following fertilization. As is typical of most maternal mRNAs, Oct4 mRNA levels drop 
dramatically after fertilization. Nevertheless, Oct4 protein is detectable in the nuclei of 2-cell 
embryos. Zygotic Oct4 expression is activated prior to the 8-cell stage, when levels of both 
mRNA and protein increase significantly in the nucleus. Expression of Oct4 is abundant and 
uniform in all cells of the embryo through the morula stage (32–64 cells) (Scholer, Hatzopoulos et 
al. 1989; Rosner, Vigano et al. 1990; Palmieri, Peter et al. 1994).  
The first differentiation step occurs when the trophectoderm splits from the inner cell mass. Here 
the Oct4 expression stays restricted to the pluripotent tissue – the inner cell mass. Oct4 
expression is then restricted to the primitive ectoderm although it is transiently expressed in high 
levels in the primitive endoderm (Palmieri, Peter et al. 1994). In the primitive ectoderm, Oct4 
expression persists through day 7,5 p.c. in the presomitic mesoderm, decreasing anteriorly to 
posteriorly as somites form (Scholer, Dressler et al. 1990). The phenomenon of stem cell-specific 
expression can be observed during the whole development. Oct4 is being expressed in totipotent 
and pluripotent lineages and is being downregulated as soon as tissues differentiate (Scholer, 
Hatzopoulos et al. 1989). In contrast to the immediate downregulation of Oct4 in trophectodermal 
and somatic lineages, Oct4 protein levels are increased initially in cells of the premigratory 
hypoblast (Palmieri, Peter et al. 1994; Herr and Cleary 1995). The transient upregulation in the 
primitive endoderm, in contrast to the downregulation in the trophectoderm and other tissues, 
suggest that it is not a repression of Oct4 that results in differentiation but more the continuous 
level of Oct4 expression that prevents differentiation. In adult mice, Oct4 is only expressed in 
germ cell precursors (Ovitt and Scholer 1998).  
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Oct4 expression can be detected in many germ cell tumors and somatic tumors such as lung 
cancer, breast cancer, bladder cancer etc. (Atlasi, Mowla et al. 2007; Chen, Hsu et al. 2008; 
Wang, Meng et al. 2010). Activation of Oct4 in epithelial tissues of adult mice results in dysplastic 
growth. These dysplastic tumors are dependent on continuous Oct4 expression (Hochedlinger, 
Yamada et al. 2005). Dysplastic lesions show an expansion of progenitor cells and increased ß-
catenin transcriptional activity. In the intestine, Oct4 expression causes dysplasia by inhibiting 
cellular differentiation in a manner similar to that in embryonic cells. Data indicates that adult 
progenitor cells remain competent to respond to Oct4 protein, suggesting Oct4 to be a potent 
proto-oncogene (Hochedlinger, Yamada et al. 2005). Also in cultured embryonic stem cells, the 
Oct4 expression correlates with the differentiation potential. 
These findings are supported by knock out experiments of Oct4 in mouse embryos. Oct4 
deficient embryos develop until the blastocyst stage, but when the first differentiation step occurs 
– when the trophectoderm splits from the ICM – they are unable to maintain the pluripotent cells 
of the ICM and differentiate into trophectoderm. This	   demonstrates that Oct4 expression is 
essential for the maintenance of potency during early development (Nichols, Zevnik et al. 1998). 
Overexpression of more than 1,5-fold of Oct4 induces differentiation to primitive endoderm or 
mesoderm (Niwa, Miyazaki et al. 2000). Thus a critical amount of Oct4 expression is necessary 
to maintain stem cell pluripotency. Up and down regulation induces divergent developmental 
programs.  Oct4 expression is therefore associated with the undifferentiated or differentiating 
Figure 4: Germline-specific expression 
of Oct4  
Boxes: cells and tissues representing the germline; 
hatched boxes and circles: cells and tissues 
expressing Oct4; in tissues and cells that are not 
framed, expression of Oct4 is not detectable or 
strongly reduced; expression of Oct4 was not 
investigated in the zygote and in the morula. The 
figure was modified from Scholer et al. (1990). 
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state - in vivo as well as in vitro. Thus, proliferation, differentiation, and migration are three 
processes in which Oct4 might be involved during the formation of germ layers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.3 Target genes of Oct4 
The Oct4 protein carries out a dual function, acting in vivo both as a transcriptional activator as 
well as a transcriptional repressor (Ben-Shushan, Thompson et al. 1998).  
Recent studies used a functional genomic approach in a human ES cell line to identify Oct4 
dependent genes. More than 1,000 genes were identified, including targets regulated directly by 
Oct4 either positively (e.g. Nanog, Sox2, Rex1, LEFTB, LEFTA/EBAF DPPA4, THY1, and 
TDGF1) or negatively (e.g. Cdx2, EOMES, BMP4, Tbx18, FGF8, Brachyury [T], Dkk1, HLX1, 
GATA6, ID2, and DLX5), as well as targets for the Oct4-associated stem cell regulators Sox2 and 
Nanog.  
This data suggest involvement in multiple signaling pathway, e.g. through Dkk1, which is a 
negative regulator of Wnt signaling, BMP4 that belongs to the transforming growth factor-ß (TGF- 
ß) family and FGF8 that is part of the fibroblast growth factor signaling (Kawabata, Imamura et al. 
1998; Niehrs 1999). These pathways are implicated in regulating human ESC differentiation. 
Furthermore, a number of differentially expressed genes that are involved in epigenetics, 
chromatin remodeling, apoptosis, and metabolism were identified (Babaie, Herwig et al. 2007).  
 
 
 
 
Primitive endoderm/ 
Mesoderm 
Pluripotent stem cell 
Trophectoderm 
    1,5-fold upregulation  
    of Oct4 protein levels 
0,5-fold downregulation          
of Oct4 protein levels 
Figure 5: For the maintenance of pluripotency Oct4 levels need to be well regulated.  
If Oct4 protein levels are upregulation more than 1,5-fold, differentiation is triggered into primitive 
endoderm and mesoderm. Downregulation of more than 0,5-fold, results in the formation of 
trophectoderm. The figure was modified from Niwa, Miyazaki et al. (2000) 
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Wnt signaling plays an important role in early development and is involved in axis formation 
(Harland and Gerhart 1997). It was shown that activation of the Wnt/ß-catenin signaling pathway 
can cause embryonic stem cells to remain pluripotent under conditions that would normally 
induce differentiation (Kielman, Rindapaa et al. 2002; Hao, Li et al. 2006; Takao, Yokota et al. 
2007). 
Recently, published data highlighted the importance of a cross talk between Oct4 and the Wnt/ß-
catenin signaling pathway. Oct4 facilitates proteasomal degradation of ß-catenin by specific 
interaction. Thereby downregulation of Oct4 results in increased ß-catenin levels leading to 
enhanced Wnt/ß-catenin signaling. Reduction of ß-catenin levels was also achieved by 
overexpression of Xenopus Oct25 (Abu-Remaileh, Gerson et al. 2010).  
 
 
2.6 Xenopus laevis as a model organism 
Since Oct proteins are known to influence early development, it is favorable to study their function 
in a model organism that develops extra-uterine. Additionally, injection techniques must be 
established for injecting RNA into the egg cell. For the evaluation of observed phenotypes, it is 
advisable to choose a model organism whose early development is well studied from a 
macroscopic and molecular point of view. 
The African clawed frog Xenopus laevis has been one of the most favored model organisms for 
vertebrate experimental embryology over the past decades. Major insights into early 
embryogenesis like signaling events important for body axis determination or germ layer 
formation were obtained from studies with Xenopus (for review see (Heasman 2006)).  
Regarding embryological studies, the major advantage of Xenopus over other model organisms, 
like the mouse, is that the embryos develop extra-uterine. High numbers of eggs can be obtained 
from one female frog and can be fertilized in vitro at the same time and thus offer the synchrony 
of clutch. These features allow the performance of large-scale experiments. Existing fate maps 
enable the prediction of cell fate for each cell of the early embryo making it possible to manipulate 
selectively specific parts of the embryo. Embryos are relatively large (1-2 mm in diameter), 
develop rapidly and can be cultured in semi-sterile conditions what makes them easy to be 
manipulated e.g. by RNA injections.  
These features make it an ideal model organism for further evaluating the molecular functions of 
Xenopus Oct proteins in vivo. 
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2.6.1 Early development of Xenopus laevis embryos 
Figure 6 shows an overview of the Xenopus live cycle. The embryos are staged according to the 
normal table by Nieuwkoop and Faber (Niewkoop and Faber 1994). After fertilization, twelve 
subsequent cleavage divisions take place. In this cleavage phase, cells divide very rapidly every 
30min. The cell cycle during this first phase consists of only S-phase and M-phase. Transcription 
does not start until 4000-cell stage, the so-called mid-blastula transition (MBT) hence a maternal 
pool of mRNAs is essential for early pattern formation. In Xenopus, the future germ layer domains 
are specified early by asymmetric localization of maternal mRNAs such as Vg1, VegT and Wnt11 
which provide a blueprint for development by a specific positioning in the oocyte (Joseph and 
Melton 1998; Xanthos, Kofron et al. 2001; Dupont, Zacchigna et al. 2005; Tao, Yokota et al. 
2005).   
At MBT, the cell divisions slow down to about 60-90min and the cell cycle is separated into the 
four phases G1, S, G2 and M. During this stage of development, cells are already committed, but 
not yet determined to their future germ layer. During blastula stage a cavity called the blastocoel 
develops. The mid-blastula embryo has three regions, the animal cap (which forms the roof of the 
blastocoel), the equatorial or marginal zone (the walls of the blastocoel) and the vegetal mass 
(the blastocoel floor). Gastrulation starts at about 10 hours post fertilization (hpf). During this 
phase, major cell rearrangements occur. A blastopore is formed through which the endoderm and 
mesoderm invaginate. The invaginated dorsal mesoderm induces development of the neural 
plate in the overlying ectoderm. Through this process, the basic body plan of the tadpole is 
established. A fundamental aspect in the development of all triploblastic organisms is that cells 
have to maintain a non-committed state prior to gastrulation. 
At about 15hpf, the neural tube folds up, which gives rise to the brain and the spinal cord. During 
those stages, the organs are also formed. Organogenesis mainly takes place from 21hpf 
onwards. The tadpole hatches at the age of about 48hpf. After about 38 days, changes in the 
environment, such as nutrient levels, induce the secretion of thyroid hormone. This leads to 
metamorphosis, which results in effects like the tail destruction, lung enlargement and ossification 
of the skull. The frogs are sexually mature after about 2 years. This summary is in essence taken 
from books written by Nieuwkoop and Wolpert (Niewkoop and Faber 1994; Wolpert 1998). 
Introduction 
 
17 
 
 
 
 
2.6.2 From totipotent cells to multicellular organisms - linage commitment and 
differentiation in Xenopus laevis embryos  
The development of a multicellular organism is a tightly controlled spatial and temporal process. It 
starts with a single, totipotent cell — the fertilized egg. Through subsequent cell divisions, the 
zygote gives rise to a complex organism. The developmental process leading from a totipotent 
cell to specialized cell types is called differentiation. This requires multiple successive events that 
result in the commitment of cells and finally leads to differentiated cell types. The process of 
commitment is subdivided into two stages. First, cells are specified – a step that is still reversible. 
A cell or a tissue is defined as specified, when it can differentiate autonomously in a neutral 
environment. The second step of commitment is called determination. Cells are considered to be 
determined, when they can differentiate autonomously even when placed in a non-neutral 
environment.  
Competence – the ability of cells to respond to an inducing signal – and induction – the change in 
behavior of a group of cells – are important mechanistic principles of the development from a 
totipotent zygote to a multicellular organism (for detailed information see (Gilbert 2006)). A 
Figure 6: Xenopus laevis development.  
Illustrated are the major steps in Xenopus laevis development. Numbers in parentheses indicate the 
timing after fertilization. The figure was adapted from Mereau, Le Sommer et al. (2007) 
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fundamental aspect in the development of all triploblastic organisms is that cells have to maintain 
a non-committed state prior to gastrulation. 
 
Although all mid-blastula cells are pluripotent, explants of the animal cap of Xenopus embryos 
form ectodermal derivatives in culture, while equatorial explants form mesoderm and vegetal 
explants form endoderm, indicating that they are already specified (Heasman, Wylie et al. 1984). 
Embryonic cells prior to gastrulation have the capacity to respond to various signaling pathways 
indicating that cell fate is not determined (Snape, Wylie et al. 1987; Gardner and Beddington 
1988). The fate of ectoderm is reversible up to the early gastrula stage. When labeled single 
animal pole blastomeres from X. laevis blastulae are transplanted into the blastocoel of late 
blastula host embryos, the daughter cells of the transplanted blastomeres contribute to all three 
germ-cell layers. This data indicates, in agreement with the transplantation and induction 
experiments, that cells are still pluripotent at early gastrula stage.  At later stages, the fate of the 
transplanted animal cells becomes restricted solely to ectoderm (Snape, Wylie et al. 1987). 
At about the same time of development, endodermal cells become restricted to endoderm when 
transplanted (Heasman, Wylie et al. 1984; Snape, Wylie et al. 1987).  
The marginal zone is specified as mesoderm early in the development process by factors located 
after cortical rotation in the marginal zone (e.g. FGF and BMP), without induction by the 
endoderm. Isolated marginal zones from X. laevis have the capacity for self-differentiation from 
the early blastula stage onwards, which shows that mesoderm is determined before the mid-
blastula transition (Nakamura, Takasaki et al. 1978).  
 
Although the temporo-spatial pattern of linage commitment and differentiation has been 
extensively studied in Xenopus laevis, the understanding of molecular mechanisms controlling 
the precise timing of these events remains incomplete. Given the high degree of evolutionary 
conservation among vertebrates, Xenopus laevis offers an attractive alternative to investigate 
mechanisms of pluripotency and lineage-commitment in a more accessible non-mammalian 
model organism.  
 
 
2.7 Oct4 homologs in Xenopus laevis embryos 
In Xenopus embryos three POU factors belonging to subclass V are known: Oct25 (Hinkley, 
Martin et al. 1992), Oct60 (Whitfield, Heasman et al. 1993), Oct91 (Frank and Harland 1992). In 
the last years, a number of publications have addressed the issue whether Oct4-related POU V 
proteins in non-mammalian vertebrates have conserved functions. First evidence for this came 
from the demonstration that Xenopus Oct4-related proteins can partially substitute for Oct4 in 
mouse cells and thereby prevented these ES-cells from differentiation.  Moreover POU V proteins 
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are known to regulate similar genes in ES cells and Xenopus embryos and different POU V 
proteins are capable of rescuing the Xenopus POU V knockdown phenotype (Morrison and 
Brickman 2006). 
These experiments indicate that the unique ability of Oct4 to maintain ES cell pluripotency is 
derived from an ancestral function of this class of proteins. 
 
2.7.1 Sequential homologies of Xenopus and mouse Oct proteins 
The three Xenopus Oct4 homologs are similar in size - ranging from 47.3 to 49.5 kDa - and 
amino acid composition (Hinkley, Martin et al. 1992). Furthermore, they have a high degree of 
sequence homologies compared to Oct4. Comparing mouse and Xenopus Oct proteins, identity 
is immediately apparent in the POUs and POUh domains. Outside these regions there exists only 
weaker homology. The predicted protein sequences are more highly related to each other than 
they are to the sequences of other POU-domain proteins.  
The POU domains of Xenopus Oct proteins display approximately 70% amino acid identities 
relative to each other, the complete sequence approximately 35% with Oct91 and Oct25 showing 
a higher degree of sequence homologies than Oct60 compared to Oct25 and Oct91. Comparing 
the POU domains of mouse Oct4 and Xenopus Oct proteins, homologies range from 57,7% 
(Oct60) to 66% (Oct91) (Morrison and Brickman 2006). Comparing the complete protein 
sequence, homologies are around 32%.  
 
      
 
 
2.7.2 Expression profiles of Xenopus Oct proteins 
Oct25 and Oct91 are expressed zygotically and transcripts are detectable in gastrula and neurula 
stage embryos. Oct25 is expressed from late oocyte to early neurula stage showing a maximum 
of zygotic transcripts during the early gastrula stage (Hinkley, Martin et al. 1992).  
Oct91 is activated at early gastrula stage and rises to peak expression levels at late gastrula 
(Frank and Harland 1992). Both proteins are expressed in the animal and marginal zone. They 
continue to be expressed throughout the process of gastrulation but only in cells that have not 
Table 1:   Protein sequence alignment of mammalian Oct4, Xenopus and Zebrafish POU 
proteins.  
The Table was modified from Morrison and Brickman (2006). 
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undergone involution. Expression is downregulated as cells begin the process of involution and 
commitment to their germ layer fate (Morrison and Brickman 2006). 
The expression pattern of Oct60 is unique among the Xenopus POU-genes. Oct60 is expressed 
maternally and is first detectable in stage V oocytes. It accumulates rapidly following fertilization 
with a peak at mid-blastula transition. The expression is restricted to the animal hemisphere in 
both unfertilized oocytes and early cleavage stage embryos and remains in the animal and 
marginal zones of the embryo. 
In the blastula, when Oct25 and Oct91 begin to accumulate, Oct60 is being downregulated. 
Oct60 protein is detectable until midgastrula (Hinkley, Martin et al. 1992; Whitfield, Heasman et 
al. 1993; Whitfield, Heasman et al. 1995).  
 
 
 
2.7.3 State of experiments on Xenopus Oct protein function 
Xenopus Oct4 homologs were first described in 1992 and since then a considerable effort has 
been undertaken to investigate their functions (Frank and Harland 1992; Hinkley, Martin et al. 
1992; Whitfield, Heasman et al. 1993). Recent work suggests that Xenopus POU-V proteins play 
a role in multiple signaling pathways involved in germ layer formation and patterning.  Research 
has highlighted their role in VegT, FGF and BMP4 signaling. 
 
VegT is a maternally expressed T-box transcription factor that is localized in the vegetal pole in 
full-grown oocytes and cleavage stages. Its depletion results in defects of primary germ layer 
formation and in loss of zygotic FGF and TGF-ß/nodal expression (Zhang, Houston et al. 1998; 
Kofron, Demel et al. 1999). Maternal VegT is known to play a key role in the formation of 
mesoderm and endoderm (Xanthos, Kofron et al. 2001). 
Figure 7: Temporal expression of 
Xenopus Oct-proteins.  
Number of transcripts per embryo, expressed 
relative to time after fertilization and stages 
according to Nieuwkoop and Faber. RNase-
resistant transcripts were quantified with a 
Betascanner and normalized to the results 
obtained with measured amounts of synthetic 
RNA. The figure was modified after Hinkley, 
Martin et al. (1992). 
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Overexpression studies indicate a possible role for Oct60 and Oct25 in the inhibition of genes 
activated by VegT and ß-Catenin. Cao et al. suggested that Oct25, VegT and Tcf3 might interact 
with each other and form repression complexes on promoters of VegT and ß-Catenin target 
genes and thereby repress mesendodermal germ layer induction and patterning. These results 
were obtained by overexpression of Oct25 and Oct60 in the vegetal pole of the embryo. Since 
Oct proteins are expressed in the animal hemisphere, while VegT is expressed in the vegetal 
half, further investigations are needed to figure out whether the interaction with VegT and Tcf3 is 
of biological relevance. Within the ectoderm, it was shown that Oct25 promotes neural fate by 
upregulating neuroectodermal genes, which prevent differentiation of neural progenitors into 
neurons (Cao, Knochel et al. 2004; Cao, Siegel et al. 2006; Cao, Siegel et al. 2007). 
 
During development, the cellular responsiveness to fibroblast growth factor (FGF) changes. In 
blastula stages FGF induces mesoderm, whereas at gastrula stages neuroectoderm is being 
induced. Oct91 was recently shown to switch FGF function from a mesoderm inducing to a neural 
inducing signal at the beginning of gastrulation. Ectopic Oct91 expression inhibits FGF induction 
of Xbra, an early mesodermal marker, while neural tissues are unaffected. Knockdown of Oct91 
expression induces Xbra, while Sip1 and Churchill, two genes regulating neural competence, are 
strongly downregulated. Morphant ectodermal explants show an extended mesodermal 
responsiveness from blastula to gastrula stages. These experiments suggest, that Oct91 is 
required for a proper temporal response to FGF signals (Snir, Ofir et al. 2006). 
 
Bone morphogenetic proteins (BMPs) and the related ligands activin/nodal are members of the 
TGF-ß family that play essential roles in the specification and subsequent patterning of the germ 
layers (Massague 2000; Kishigami and Mishina 2005). In the ectoderm of early Xenopus 
embryos, BMP promotes epidermal differentiation by inducing expression of the Msx, Dlx, Vent 
and Id families of transcription factors that are responsible for inhibition of neural differentiation 
(Ladher, Mohun et al. 1996; Feledy, Beanan et al. 1999; Luo, Matsuo-Takasaki et al. 2001) 
Oct25 inhibits the competence of ectodermal tissues to respond to BMP. BMP plays an important 
role in the regulation of ectodermal fate by inducing epidermis at the expense of neural tissue 
during gastrulation. 
Oct25 overexpression in the ectoderm after the blastula stage suppresses early BMP responses 
of ectodermal cells downstream of BMP receptor activation and promotes neural induction while 
suppressing epidermal differentiation. In contrast, inhibition of Oct25 function in the prospective 
neuroectoderm results in expansion of epidermal ectoderm at the expense of neuroectoderm. 
 
Oct proteins seem to have far reaching functions in coordinating dynamically embryonic induction 
events and germ layer formation.  Investigations so far have mainly concerned the function of 
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Oct91 and Oct25. Much less is known about the function of Oct60. Still further efforts have to be 
made to find out whether Xenopus Oct proteins also control pluripotency comparable to mouse 
Oct4 and in particular by which mechanisms this is achieved. Furthermore, it has to be elucidated 
whether the three Oct4 paralogs carry out redundant or non-overlapping functions. 
 
 
 
2.8 Objectives 
The POU transcription factor Oct4 is one of a few key regulators of cellular pluripotency in 
mammals. In Xenopus, three Oct4-related genes have been identified, which are maternally and 
zygotically expressed from fertilization to neurulation. As shown by previous work, they can 
partially substitute for Oct4 in mouse ES cells. Furthermore, recent work implicates these proteins 
in multiple signaling pathways during germ layer formation, providing a conceptual framework for 
further analysis of their functions during frog development.  
 
The goal of this work was to obtain tools for evaluating the function of Xenopus Oct proteins 
concerning the maintenance of pluripotency and germ layer formation. Therefore, I generated 
dominant activating and repressing gain of function variants for all three wild type Xenopus Oct 
proteins. Protein expression was verified in vitro as well as in vivo and their transactivating 
functions were evaluated in a luciferase assay in vivo.  
Additionally, I performed overexpression studies of Oct60 and its newly generated gain of 
function variants.  Several phenotypes were observed and analyzed by in situ hybridizations.
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3 Materials and Methods 
3.1 Laboratory Equipment 
The subsequent laboratory equipments were used. The companies are put in brackets. 
CCD camera: ProGres C14 (Zeiss) 
Centrifuges: Eppendorf centrifuge 5417C (Eppendorf); Omnifuge 2.0 RS (Haereus); Sorvall                     
RC-5B (Du Pont), Micro 22R (Hettich Zentrifugen), Optima LE-80K Ultracentrifuge (Beckman 
Coultier), PicoFuge (Stratagene) 
Developer: Curix-60 (Agfa) 
Glass injection needles: Glass 1BBL W/FIL 1.0 mm (World Precision Instrument). 
Injector: Pli-100 (Digitimer Ltd.). 
Incubator: Driblock DB1 and DB20 (Teche). 
Luminometer: Lumat LB 9501, EG&G Berthold 
Microneedle Puller: P-87 (Sutter Instrument). 
Micromanipulator: Mm-33 (Science Products). 
Microscopes: Stereomicroscopes Stemi SV6, Stemi SV11 (Zeiss), MZFCIII (Leica),  
Nylon membrane: Hybond™ N (Amersham). 
Ph-Meter: pH-Meter 761 Calimatic (Knick) 
Pipettes: Pipetman, Gilson (2µl, 20µl, 200µl, 1000µl) 
Software: Photoshop CS2 (Adobe); Illustrator CS2 (Adobe); MacVector 7.1 (Oxford    Molecular 
Group); Office 2004 for Mac (Microsoft), Endnote 9.0 (Thomson), ABI Prism Primer Express 
(Applied Biosystems) 
Sonicator: Bioruptor™ (Diagenode) 
Spectrophotometer: Nanodrop ND-1000 (PeqLab) 
 
 
3.2 Reagents 
3.2.1 Chemicals 
Agar (Difco); Agarose (Gibco/BRL); Ampicillin, Streptomycin, Bacto trypton, Yeast extract (Difco); 
Chicken serum, lamb serum (Gibco/BRL); Human chorionic gonadotropin (Sigma); Levamisol 
(Vector Laboratories), QIAzol (Qiagen)  
The subsequent fine- and bio-chemicals were ordered at the following companies:  
Fluka, Merck, Sigma-Aldrich, Roth and Biomol. 
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3.2.2 Enzymes and proteins 
The following enzymes were ordered at the companies put in brackets:  
Alkaline phosphatase (Roche); BSA fraction V, Chymostatin, Leupeptin, Pepstatin (Sigma); 
Klenow enzyme (Roche); Restriction endonuclease with 10x restriction buffer system (New 
England Bio Labs, Roche, Fermentas); RNaseA (Sigma); RNasin (Promega); T3, T7 and SP6 
RNA polymerase with 5x incubation buffer (Promega); Taq DNA polymerase with 10x PCR buffer 
(NEB), Advantage 2 Polymerase Mix (BD Bioscience Clontech), Proteinase K (Sigma); RNase 
free DNase I (NEB) and Pre-stained protein molecular weight standard (Sigma), Precision Plus 
Protein Prestained Standard (Biorad) 
 
 
3.3 Nucleic acids 
3.3.1 Size standard 
1kb ladder: GeneRuler™ 1kb DNA ladder (Fermentas)  
The DNA ladder yields the following 14 discrete fragments (in base pairs): 10000, 8000, 6000, 
5000, 4000, 3500, 3000, 2500, 2000, 1500, 1000, 750, 500, 250. 
100bp ladder: GeneRuler™ 100bp DNA ladder plus (Fermentas)  
The DNA ladder yields the following 14 discrete fragments (in base pairs): 3000, 2000, 1500, 
1200, 1031, 900, 800, 700, 600, 500, 400, 300, 200, 100.  
3.3.2 Oligonucleotides 
Oligonucleotides were synthesized by Biomers. 
Morpholino oligonucleotides were ordered from Gene Tools. 
3.3.2.1 Oligonucleotides for cloning 
Oligos for PCR-cloning of oct60 into the pCS2+-MT6 vector:       
LM 01 
                  XhoI 
5´- C TCT CGA GCA ATG GAC CAG CCC ATA -3´ sense; 25-mer 
LM 02 
                   XbaI 
5´- CC TCT AGA TCA GCC GGT CAG GAC -3´ reverse; 23-mer 
 
Oligos for PCR-cloning of oct25 into the pCS2+-MT6 vector: 
LM 03 
                    XhoI 
5´- C TCT CGA GCA ATG TAC AGC CAA CAG -3´ sense; 25-mer 
LM 04 
                    XbaI 
5´- CC TCT AGA TCA GCC AAT GTG GC -3´ reverse; 22-mer 
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Oligos for PCR-cloning of oct91 into the pCS2+-MT6 vector:  
LM 05 
                    XhoI 
5´- C TCT CGA GCA ATG TAT AAC CAA CAG -3´ sense; 25-mer 
LM 06 
                    XbaI 
5´- CC TCT AGA CTA GTT GCC TTG GTT AC -3´ reverse; 25-mer 
 
Remarks: Primers LM 01,02,03,04,05,06 amplify the oct cDNA so that it can be cloned into the 
pCS2+-MT vector downstream of the enR/vp16/gr domain. XhoI and XbaI can be used for 
cloning.  
 
Oligos for PCR-cloning of the gr repression domain into the pCS2+-MT6 vector:             
RR 149 
                   StuI          MluI            SpeI 
5´-GA AGG CCT ACG CGT ACT AGT CCC TCT GAA AAT-3´ sense; 32-mer 
LM 07 
                 XhoI 
5´- CTC TCG AGC CTT TTG ATG AAA C -3´ reverse; 29-mer 
 
Oligos for PCR-cloning of the vp16- activation domain into the pCS2+-MT6 vector: 
RR 177 
                   StuI     SpeI      
5´-GA AGG CCT ACT AGT ACG GCC CCC CCG ACC GAT-3´ sense; 31-mer 
LM 08 
                   XhoI 
5´- C CGC TCG AGC CCC ACC GTA CTC GTC AAT – 3´ reverse; 28-mer 
 
Oligos for PCR-cloning of oct60 into the pCS2+-MT6-enR/vp16 vector: 
LM 09 
                  XhoI 
5`- C TCT CGA GCA GGA ATG ACC CTT GAG GA- 3´ sense;  27-mer 
LM 10 
                  XbaI 
5´- CC TCT AGA CTA GGA CAT TCT GAA TTT GC  - 3´ reverse; 28-mer 
 
Oligos for PCR-cloning of oct25 into the pCS2+-MT6-enR/vp16 vector: 
LM 11 
                   XhoI 
5´- C TCT CGA GCA GTT CCC AGC GAA TCA GAA – 3´ sense; 28-mer 
LM 12 
                   XbaI 
5´- CC TCT AGA CTA GGG CAT TCC CTG ACG CTT – 3´ reverse; 29-mer 
 
Oligos for PCR-cloning of oct91 in pCS2+-MT6-enR/vp16 vector: 
LM 13 
                   XhoI 
5´- C TCT CGA GCA GCC CCT AAT TCT GGG GAG – 3´ sense; 28-mer 
LM 14 
                  XbaI 
5´- CC TCT AGA CTA ATA GGG GTA CAC CTG GCG – 3´ reverse; 29-mer 
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3.3.2.2 Antisense morpholino oligonucleotides 
All antisense morpholino oligonucleotides were designed according to Morrison et al., 2006 and 
provided by Gene Tools.  
oct60-MO 5´-GTACAATATGGGCTGGTCCATCTCC-3´ 
oct25-MO 5´-ACATGGTGTCCAAGAGCTTGCAGTC-3´ 
oct91-MO 5´-GTAGGTCTGTTGGTTATACATGATC-3´ 
 
3.3.3 Plasmids 
Unless stated otherwise, plasmids were constructed and cloned in our lab. 
3.3.3.1 Vectors for cloning 
pCS2+MT6 (Rupp, Snider et al. 1994): The vector backbone is from pBluescript II KS+  
pCRII-TOPO-vector (Invitrogen) 
3.3.3.2 Plasmids for in vitro transcription 
 
 
 
 
 
 
Plasmid PCR primers for 
amplification 
Enzymes used 
for cloning 
Linearized 
by 
Polymerase 
pCS2+-MT-EnR   SacII SP6 
pCS2+-MT-VP16 RR 177 & LM 08 StuI, XhoI NotI SP6 
pCS2+-MT-GR RR149 & LM 07 StuI, XhoI NotI SP6 
pCS2+-MT-Oct60 LM 01 & LM 02 XhoI, XbaI NotI SP6 
pCS2+-MT-Oct25 LM 03 & LM 04 XhoI, XbaI NotI SP6 
pCS2+-MT-Oct91 LM 05 & LM 06 XhoI, XbaI NotI SP6 
pCS2+-MT-EnR-Oct60 LM 09 & LM 10 StuI, XhoI, XbaI SacII SP6 
pCS2+-MT-EnR-Oct25 LM 11 & LM 12 StuI, XhoI, XbaI SacII SP6 
pCS2+-MT-EnR-Oct91 LM 13 & LM 14 StuI, XhoI, XbaI SacII SP6 
pCS2+-MT-VP16-Oct60 LM 09 & LM 10 StuI, XhoI, XbaI NotI SP6 
pCS2+-MT-VP16-Oct25 LM 11 & LM 12 StuI, XhoI, XbaI NotI SP6 
pCS2+-MT-VP16-Oct91 LM 13 & LM 14 StuI, XhoI, XbaI NotI SP6 
pCS2+-MT-GR-Oct60  StuI, XhoI, XbaI NotI SP6 
pCS2+-MT-GR-Oct25  StuI, XhoI, XbaI NotI SP6 
pCS2+-MT-GR-Oct91  StuI, XhoI, XbaI NotI SP6 
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3.3.3.3 Plasmids for dig-labeled RNA in situ hybridization probes 
RNA antisense probe Plasmids linearized by Polymerase 
Cardiac actin PvuII SP6 
Endodermin EcoR1 T7 
N-ß-tubulin BamH1 T3 
Xbra  EcoR1 T7 
 
3.3.3.1 Plasmids for the luciferase assay 
6w-tk-luc: The 6w enhancer contains 6 copies of oligonucleotides with an octamer binding motif 
from the mouse Ig heavy chain gene enhancer (Tomilin, Remenyi et al. 2000). The promoters are 
linked to the luciferase reporter gene. The promoter was fused with the luciferase gene. 
6xMORE-tk-luc: The more promoter is a palindromic Oct recognition element 
(ATGCATATGCAT) that mediates assembly of stable Oct homodimers and heterodimers and 
leads to strong transcriptional activation. The promoter was fused with the luciferase gene. 
Both plasmids were kindly provided by the lab of Hans Schöler. 
 
 
3.4 Handling of bacteria 
Preparations of competent cells and transformation have been performed according to standard 
methods (Sambrook et al., 1989). 
 
3.4.1 Bacteria strains 
Summary of Escherichia coli strains  
Strain Genotype Company 
BL21(DE3) B F- dcm ompT hsdS(rB- mB-) gal (DE3) Novagene 
One Shot  E. coli  
F-φ80lacZΔM15Δ(lacZYA-argF)U169 recA1 endA1 
hsdR17(rk-,mk+) phoA supE44thi-1 gyrA96 relA1 tonA 
Invitrogene 
JM110 
rpsL (Strr) thr leu thi-1 lacY galK galT ara tonA tsx dam 
dcm supE44 Δ(lac-proAB) [F´ traD36 proAB 
lacIqZΔM15] 
Stratagene 
XL1Blue 
F'::TN10 proA+B+laclq Δ(lacZ)M15/recA1 end A1 
gyrA96(NalR) thi hadR17 (rK-mK-) glnV44 relA1 lac 
Stratagene 
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3.5 Antibodies 
3.5.1.1 Antibodies for in situ Hybridization 
Sheep anti-Digoxigenin Fab fragment coupled with alkaline phosphatase (Roche);  
3.5.1.2 Antibodies for Western Blot analysis 
Primary anti-myc-tag-antibody: c-Myc 9E10 (WB 1:100), monoclonal (Evan, Lewis et al. 1985) 
Secondary antibody: peroxidase-conjugated AffiniPure Goat-Anti Mouse IgG (H+L) (1:10000)     
(Dianova) 
 
 
3.6 Molecular biological methods 
3.6.1 Solutions 
AB-buffer: 80% TBSX, 15% heat-inactivated lamb serum, 5% Xenopus egg extract. 
AP-Buffer: 100mM trichlorethane Tris/HCl 9.5; 100mM NaCl; 50mM MgCl2 
Bleaching solution: 1% H2O2; 5% Formamid; 0.5x SSC 
DEPC-H2O: ddH2O with 0.1% Diethylpyrocarbonat (DEPC) agitated at 23°C over night and 
autoclaved afterwards. 
10mM DIG NTP mixture: 10mM CTP, GTP, ATP, 6.5mM UTP and 3.5mM Dig-11-UTP. 
Hybridizing solution: 5x SSC, 50% formamide, 1% Boehringer block, 0.1% Torula RNA, 0.01% 
Heparin, 0.1% Tween-20, 0.1% CHAPS, 5mM EDTA. 
Lamb Serum: Heat-inactivated lamb serum (30 min with 56°C), stored at -20°C. 
MEMFA: 0.1M 3-(N-Morpholino)-propanesulfonic acid (MOPS), 2mM EGTA, 1mM MgSO4, 3.7% 
formaldehyde pH 7.4  
Paraformaldehyde: 4% paraformaldehyde in PBSw  
PBS: 137mM NaCl, 2.7mM KCl, 8mM Na2HPO4, 1.7mM KH2PO4 pH 7.2  
PBSw: 1xPBS, 0.1% Tween-20  
PCI: 50% phenol, 48% chloroform, 2% isoamyl alcohol. 
Proteinase K: 10µg/ml Proteinase K in PBSw 
20xSSC: 3M NaCl, 0.3M sodium citrate (pH 7.0 at 23°C). 
TBS: 50mM trichloroethylene (Tris)/HCl, 150mM of NaCl (pH 7.5 at 23°C). 
TBSX: 1xTBS, 0.1% Triton X-100 (pH 7.5 at 23°C). 
TE: 1mM EDTA, 10mM of Tris/HCl (pH 8.0 at 23°C). 
TBE: 100mM Tris/HCl, 83mM borate, 0.1mM EDTA (pH 8.6 at 23°C). 
Xenopus egg extract for in situ hybridization: unfertilized eggs were dejellied with 
2% cysteine, washed 3 times, 1 volume of PBS was added. Then they were lysed by 10 strokes 
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of a Dounce homogenisators, and centrifuged (7500xg, Sorvall Rc-5b, rotors SS-34, 10000rpm, 
4°C, 10min). The supernatant was transferred into a fresh centrifuge tube and recentrifuged twice 
under the same conditions. The supernatant was aliquoted and stored at -20°C. 
 
3.6.2  Isolation of nucleic acids 
3.6.2.1 Mini-preparation with Qiagen kit 
Plasmid DNA mini-preparations were carried out using the QIA prep spin Miniprep kit (250) 
(Cat.No. 27106). 
 
3.6.3 Analysis and manipulation of nucleic acids 
3.6.3.1 Cloning methods 
The cloning of DNA has been performed according to standard methods (Sambrook et al., 1989). 
3.6.3.2 Gel electrophoresis of nucleic acids 
DNA or in vitro synthesized RNA was isolated in horizontal agarose gel. Depending upon 
fragment size, one to two percent TBE agarose gels were used. After electrophoresis the gels 
were photographed. 1kb or 100bp DNA ladder was used as size standard. 
3.6.3.3 Isolation of DNA fragments from agarose gel 
In order to isolate DNA fragments after electrophoresis from agarose gel, the appropriate bands 
were cut out under long-wave UV light. The DNA was extracted from the gel with QIAquick gel 
extraction kit (250) (Cat.No. 28706). 
 
3.6.4 Polymerase chain reaction (PCR)  
3.6.4.1 PCR amplification of DNA fragments for cloning 
The reaction was accomplished in a total volume of 50µl. The reaction mixture contained 100ng 
template DNA, 25pmol each primer, 0.5mM dNTPs, 1U Advantage Taq Polymerase (Invitrogen) 
or Taq polymerase (NEB) and 1x of the supplied buffer. The program was 95ºC 30 sec, xºC 
30sec (annealing temperature depended on the primers used), 68°C/72ºC 1min/kb, 30 cycles. 
The PCR products were digested with the suitable endonuclease and separated on agarose gel. 
Subsequently, the desired DNA fragment was isolated. 
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3.6.5 In vitro transcription 
3.6.5.1 In vitro transcription for microinjection 
Capped mRNAs for microinjection were in vitro transcribed with RNA polymerase. Reactions 
were set up as following: in a total volume of 50µl, 4µg linearized plasmid DNA, 1x of the supplied 
transcription buffer, 0.5mM dNTPs, 2.5mM RNA cap structure analogue, 10mM DTT, 20U 
RNAsin and 40U Sp6 or 60U T3 or T7 RNA Polymerase. The reaction was incubated for 4 hours 
at 37°C. Subsequently, the template DNA was digested with 10U RNase free DNaseI for 30min 
at 37°C. The RNA was purified with the RNeasy Kit Mini (Qiagen) (Cat.No.74104). The 
concentration of the RNA was determined by NanoDrop ND-1000 spectrophotometer (Peqlab).  
3.6.5.2 In vitro transcription of dig labeled RNA probes 
Plasmids were linearized and antisense RNA was generated by in vitro transcription. The 
reactions were set up in a total volume of 50µl as following: 4µg linearized plasmid DNA, 1x of 
the supplied transcription buffer, 0.1mM Dig-NTPs, 20U RNAsin and 20U SP6 or T3 or T7 RNA 
Polymerase. The reactions were incubated at 37°C for 4h and purified with the RNeasy Kit Mini 
(Qiagen). 
 
3.6.6 RNA in situ hybridization 
The embryos were fixed in fresh MEMFA for 1.5-2 hours and washed afterwards with PBS 
3x5min. The dehydration of the embryos was performed over a period of one hour by replacing 
the PBS subsequently with 100% ethanol. The lipid membranes were dissolved overnight at 
-20°C in 100% ethanol. The embryos were rehydrated through a 75, 50, 25% ethanol series in 
PBSw. Each ethanol step was incubated for 5min at room temperature.  Afterwards 3 washes 
with for 5min with PBSw were performed. The solution was then changed to Proteinase K in 
PBSw and incubated for 20min at 17°C, followed by a short rinse with PBSw. Again two washes 
for 5min each were performed with PBSw. After the Proteinase K digest the embryos were 
refixed with paraformaldehyde for 20min. A short rinse with PBSw was performed followed by 
subsequent washing in PBSw for 5x5min. The PBSw was replaced with hybridization solution 
(50% PBSw: 50% hybridization solution; 100% hybridization 3min each step). 0.5ml of fresh 
hybridization solution was added to each vial and incubated at 65°C for 1h to inactivate 
endogenous phosphatases. The embryos were then prehybridized at 60°C for 2-6h. To 100µl of 
hybridization solution 30-50ng of RNA probe was added and incubated at 95°C for 2-5min, 
cooled immediately afterward on ice and added to the embryos in prehybridization solution. The 
RNA probe was hybridized to the mRNA over night at 60°C. To remove excessive RNA probe, 
the embryos are washed the following after the hybridization:  2xSSC; 0.1% CHAPS short rinse; 
2xSSC;0.1% CHAPS for 20min; short rinse with 0.2xSSC;0.1% CHAPS; 2x for 30min at 60°C in 
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0.2xSSC;0.1% CHAPS. Prior to the antibody binding the embryos were transferred into TBSX 
(short Rinse in 50% TBS: 50% 0.2xSSC; 0.1% CHAPS), washed in TBS for 5min and rinsed in 
TBSx. To block unspecific antibody binding sites, the embryos were incubated in antibody buffer 
(0.5ml per vial) for 2h at 4°C. In parallel, AP-conjugated anti-DIG antibody (1/5000 diluted) was 
preabsorbed against Xenopus proteins present in antibody solution. 0.5ml of preabsorbed 
antibody solution was added to the embryos and incubated overnight at 4°C. After antibody 
binding, the embryos were briefly rinsed with TBSx and washed 6 times for 1h in TBSx. Embryos 
were shortly rinsed in AP buffer and equilibrated for 15min. AP-buffer was replaced with 0.5ml 
staining solution and incubated overnight until or to 3 days at 17°C in the dark. The staining 
reaction was stopped by washing twice in PBS for 10min. If the embryos were over-stained, 
some color was removed by washing the embryos in 75% ethanol in PBS for 20min. The stain 
was fixed in MEMFA for 90min. The embryos were bleached in bleaching solution on a light box 
for 2h. The bleach solution was washed off with PBS 3x5min. For long-term storage, the embryos 
were transferred to PBSw containing 0.2% azide and kept at 4°C. 
 
 
3.7 Protein analysis 
3.7.1 Solutions 
3x Lämmli buffer: 150mM Tris pH6.8, 300mM DTT, 4% SDS, 30% glycerol 
Chemiluminescence reagents (ECL): Luminol solution: 0.44g luminol in 10ml DMSO, freeze in 
1ml aliquots, store at -20°C; p-coumaric acid: 0.15g in 10ml of DMSO, freeze in 0.44ml aliquots, 
store at -20°C; 
solution 1 (100ml): 10ml 1M Tris/HCl pH 8.5, 1ml luminol, 0.44ml p-coumaric acid;  
solution 2 (100ml): 10ml 1M HTris/Cl pH 8.5, 60µl 30% H2O2 
 
3.7.2 In vitro translation 
In vitro translations of proteins were performed with the TNT® SP6 Quick Coupled 
Transcription/Translation System (Promega) according to the manufacturer’s protocol. 
 
3.7.3 Protein extraction for Western Blot Analysis  
For each condition 5 embryos were collected at the required stage. 50 µl  of embryo-lysis-buffer 
for Western blot analysis were added per embryo (250 µ l starting volume/ 5 embryos/ tube). 
Embryos were lysed by pipetting with a 200µl Pipetman yellow tip and sonication, using the 
Bioruptor 3x30sec at high level. The cell debris was removed by a centrifugation step for 10min at 
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4°C at full speed. 250µl of 1,1,2 trichlortrifluorethane were added to the supernatant, vortexed 
and centrifuged for 10min at 4°C at full speed. The upper, aequous phase containing the protein 
was separated into a new tube and precipitated by Wessel-Flügge-precipitation. The samples 
were mixed with 1 vol ddH2O, 2 vol methanol, 1 vol CHCI3, vortexed and centrifuged for 5min at 
full speed at 4°C. The upper phase was discarded and 3 vol of methanol were added to the 
remaining solution and vortexed. After centrifugation the white protein pellet was air-dried and 
resolved in 3x Lämmli buffer, incubated for 10min at 95°C, shock frozen with liquid nitrogen and 
stored at -80°C.   
 
3.7.4 SDS-PAGE and Western Blot Analysis 
SDS-PAGE (SDS-polyacrylamide gel electrophoresis) and Western blot analysis were carried out 
according to standard protocols (Sambrook, Fritsch et al. 1989). After Protein extraction a 10% 
SDS-polyacrylamide gel was used to resolve the protein with a voltage of 120V/400mA for 90 
minutes. Proteins were transferred on to a PVDF membrane by the wet transfer system from 
BioRad for 60 minutes at 70V/400mA and 4°C. Afterwards the membrane was transferred into 
5% milk in PBSw for one hour to block nonspecific binding sides. The membrane was transferred 
into 5% milk in PBSw with the primary anti-myc-tag-antibody (1:100) and incubated at 4°C 
overnight. Thereupon the membrane was washed with PBSw three times for 10 minutes each 
and then incubated with the secondary peroxidase-conjugated Goat-Anti Mouse IgG antibody 
(1:1000) for two hours at room temperature. The membrane was washed in PBSw three times for 
20 minutes each. Signals were detected by enhanced chemiluminescence solution in a relation of 
1:1 after exposing the membrane to X-ray film (Super-RX Fuji medical X-ray film). Films were 
developed according to the manufacturer’s protocol. 
 
3.7.5 Luciferase assay 
Injected embryos were frozen in liquid nitrogen and stored at -80°C until further analysis. For 
every condition three samples, consisting of 5 embryos each, were analyzed in parallel.  
Preparation of cell lysates and measurements were performed using the  Dual-Luciferase™ 
Reporter Assay System (Promega) and a Luminometer (Lumat LB 9501, EG&G Berthold). Lysis 
buffer (PLB), luciferase assay reagent II (LARII) and stop&glow reagents are part of the Dual-
Luciferase™ Reporter Assay Systems kit and were prepared according to the manufacturer`s 
protocol. 50µl of Passive Lysis Buffer (PLB) were added per embryo. Embryos were frozen and 
thawn two times followed by manual lysis by vortexing and pipetting with a 200µl Pipetman yellow 
tip. After a 10 minute incubation period on ice the cell lysate was spun for 30 seconds at 4°C full 
speed. 100µl of LARII solution were pre-dispensed into the luminometer tubes. 20µl of cell lysate 
was added and mixed by pipetting. Tubes were placed into the luminometer and firefly luciferase 
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activity was measured. 100µl of stop&glow reagent was added to record the Renilla luciferase 
activity. Means from the three different samples of each condition were assessed and the mean 
coefficient firefly / renilla activity was calculated. 
 
 
 
3.8 Histological methods 
3.8.1 Solutions 
AP buffer: 100mM Tris/HCl (pH 9.5), 50mM MgCl2, 100mM NaCl, 0.1% Tween 20, 5mM 
Levamisole. 
AP staining solution: 4.5µl NBT, 3.5µl BCIP in 1ml AP buffer. 
A-PBS: 103mM NaCl, 2.7mM KCL, 0.15mM KH2PO4, 0.7mM NaH2PO4 pH7.5 
A-PBS-T: APBS with 0.1% Tween20 
Blocking buffer: PBT plus 10% heat inactivated serum 
MEMFA: 0.1M MOPS, 2mM EGTA, 1mM MgSO4, 3.7% formaldehyde (pH7.4 at 23°C), prepare 
freshly. 
PBS: 137mM NaCl, 2.7mM KCl, 8mM Na2HPO4, 1.7mM KH2PO4 (pH7.2 at 23°C). 
PBT: PBS, 2mg/ml BSA, 0.1% Triton-X-100. 
X-Gal staining solution: 50mm K3Fe(CN)6, 50mm K4Fe(CN)6, 25µl Xgal (40mg/ml), 2µl MgCl2 
(1M) per ml PBS 
 
3.8.2 LacZ staining 
Embryos were fixed in MEMFA for 1 hour and rinsed with 1xPBS twice for 10 min each. Embryos 
were stained with X-gal staining solution in the dark at 30°C for approximately 1 hour until 
staining was completed. The staining reaction was stopped by washing 3 times in PBS for 5 
minutes each. For fixation embryos were transferred to MEMFA for another hour, washed in PBS 
three times for 10 minutes each and stored in methanol at -20°C. 
 
 
3.9 Embryological methods 
3.9.1 Solutions 
Cystein: 2% L-Cystein in 0.1xMBS (pH7.8 at 23°C, adjusted with 5M NaOH). 
Human Chorionic Gonadotropin (HCG): 1000 I.U./ml HCG in ddH2O. 
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MEMFA: 0.1M 3-(N-Morpholino)-propanesulfonic acid (MOPS), 2mM EGTA, 1mM MgSO4; 3.7% 
formaldehyde (pH 7.4 at 23°C). 
1xModified Barth’s Saline (MBS): 5mM HEPES, 88mM NaCl, 1mM KCl, 0.7mM CaCl2, 1mM 
MgSO4, 2.5mM NaHCO3 (pH 7.6 at 23°C). Add the CaCl2 before use. 
MBS/high salt: 1xMBS with 50mM NaCl 
0.1/0,5xMBS/Gentamycin: 0.1/0,5xMBS, 10µg/ml Gentamycin 
MBS/CS: 0.8xMBS high salt with 20% chicken serum, 200U Penicillin/ml, 200µg/ml streptomycin 
stored at -20°C 
 
3.9.2 Experimental animals 
Adult wild-type Xenopus laevis frogs (Xenopus Express and Nasco) were used. The frogs were 
kept in tab water with a temperature of 17-19°C and a population density of 5l water per frog. The 
animals were fed three times per week with Pondsticks Premium brittle (Interquell GmbH, 
Wehringen). 
 
3.9.3 Superovulation of female Xenopus laevis 
Egg deposition was stimulated by injection of 500-700 units of human chorionic gonadotropin 
(Sigma) into the dorsal lymph sac. Egg lying started about 12-18h later. 
 
3.9.4 Preparation of testis 
A male frog was anaesthetized in 0.1% 3-Aminobenzoeacid-ethyl-ester in ddH2O for 30min, 
cooled down in ice-cold water and killed by decapitation. The two testes were taken from the 
abdominal cavity by pulling out the yellow fat body, with which they are connected by connective 
tissues. Until use, the testes were stored in MBS/CS for maximal 7 days. 
 
3.9.5 In vitro fertilization of eggs and culture of the embryos 
For in vitro fertilization a piece of testis was minced in 1xMBS and mixed it with freshly laid eggs. 
Afterwards the embryos were cultured in 0.1xMBS at 16-23°C in 110mm Petri dish. 
 
3.9.6 Removal of the egg jelly coat 
One hour after fertilization or later, the egg jelly coat was removed in 2% cysteine solution pH 7.8 
for about 5min with gentle agitation in a conical glass flask. Embryos were washed three times 
with 0.1xMBS and cultured further in 0.1xMBS at 16-23°C. 
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3.9.7 Injection of embryos 
Injection needles (World Precision Instrument, Inc; glass thin wall W/Fil 1,0mm, 4IN) were pulled 
from capillaries with the Microneedle Puller (setting: heat:800; pull:35; vel:140; time: 139; Sutter 
Instrument, model P-87). One injection needle was placed into the holder of the injection 
equipment (Medical System, model Pi-100). The tip was broken carefully with Dumont tweezers 
(No 5) and the opening was calibrated until an injection pressure of 30psi produced an output-
volume of 5nl in a defined injection time (30ms-1s). The needle was filled with 1-2µl nucleotide 
acid containing solution shortly before the injection. Embryos were injected at two cell stage into 
the animal hemisphere.  Depending on the performed experiment one single blastomere (5nl per 
embryo) or both blastomeres (10nl per embryo) were injected twice each. After injection, the 
embryos were incubated in 0.1xMBS containing gentamycin at 16-23°C until the desired 
developmental stages in a 60mm Petri dish covered with 1% agarose in 0.1xMBS. The saline 
was changed every day to increase the survival rates of the embryos. 
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4 Results  
4.1 Molecular tools for functional interference with Xenopus Oct4 
homologs  
Oct4 plays an important role in coordinating embryonic induction processes and germ layer 
formation in mammals. Little is known about the molecular functions of Oct4 homologs in other 
vertebrates. Xenopus laevis offers several advantages in studying developmental functions.  
Mouse Oct4 was reported to act as a transcriptional activator as well as a repressor in mammals 
(Babaie, Herwig et al. 2007). The trans-activating functions of Xenopus Oct4 homologs are not 
fully understood, yet. To gain further insights into the function of Xenopus Oct proteins during 
early embryogenesis, I decided to study overexpression of the wildtype Xenopus Oct proteins as 
well as overexpression of dominant activating and dominant repressing protein variants. The idea 
of this approach is to discriminate between activating and repressing influences on the 
expression of target genes and the corresponding phenotypic changes. Assuming that Oct60 
functions as an activator as well as a repressor, fusion constructs with activating domains should 
accentuate the activating aspects and get rid of the repressive effects while vice versa fusion to a 
strong repressor domain should accentuate the repressive aspects.  
Additionally, hormone inducible transcription factor variants were cloned. The structures of the 
generated Xenopus Oct protein variants are shown in Figure 8. 
 
To generate variants of Xenopus Oct proteins with activating function, the herpes simplex virus 
VP16 protein domain was used, which is one of the most potent transcriptional activators known. 
The VP16 domain consists of 87 amino acids and is a structural component of the virion that 
activates immediate early viral gene expression (Cousens, Greaves et al. 1989).  
For transcription factor variants with repressing functions, the transactivation domain of the 
engrailed (enR) gene from Drosophila melanogaster was used (Badiani, Corbella et al. 1994; 
Conlon, Sedgwick et al. 1996; Steinbach, Ulshofer et al. 1998). The VP16 activator domain and 
the enR repression domain respectively were cloned in frame to the 5´-end of the Xenopus-oct-
cDNAs, to produce the corresponding plasmids.  
 
Furthermore, for controlling gene expression temporally, hormone inducible transcription factor 
variants were generated. These constructs are useful for analyzing gene function during 
development, particularly if effects later in development are to be examined. Injection of RNAs 
into cleavage-stage embryos generally results in immediate translation.  
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Hormone-inducible systems enable the control of protein expression in a temporal manner due to 
fusion of hormone-binding domains of steroid receptors and heterologous proteins. In the 
absence of hormone, the fusion protein is held in an inactive state, most likely due to complex 
formation with hsp90 (Cadepond, Schweizer-Groyer et al. 1991; Scherrer, Picard et al. 1993). 
Addition of hormone results in translocation of the fusion protein into the nucleus and its 
activation (Hollenberg, Cheng et al. 1993; Gammill and Sive 1997). To produce hormone 
inducible protein variants, the 259 amino acid glucocorticoid receptor domain (GR) was cloned to 
the 5´-end of the Xenopus-oct-cDNAs.  
 
 
The pCS2+-6xMT-vector was used for expression (Figure 9). It was generated for the expression 
of epitope-tagged fusion proteins in Xenopus embryos from either injected RNA or DNA (Rupp, 
Snider et al. 1994). The vector contains 6 myc tags. After expression these myc epitopes are 
specifically recognized by the 9e10 monoclonal antibody (Evan, Lewis et al. 1985). Thereby, 
detection of the overexpressed proteins is possible in vitro as well as in vivo.  An advantage of 
this approach is that different proteins can be detected with similar efficiency since the same 
epitope tag and antibody is used for all.  
                             
 
 
 
Figure 8: Expression constructs 
For the generation of constitutively activating, constitutively repressing and hormone inducible Oct protein 
variants, the enR repressor-, the vp16 activator- or the glucocorticoid receptor domain (gr) was cloned to 
the 5´end of the Xenopus oct cDNA. 
The mapped constructs were generated for each of the three Xenopus oct cDNAs. The pCS2+MT6 
expression vector was used for mRNA expression in vitro.    
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Oct-cDNAs were amplified via PCR (for primers see chapter 3.3.2.1), cloned into the dual TOPO 
vector and sequenced. The verified cDNA-inserts were released by digestion with XhoI and XbaI 
and subcloned into the pCS2+-MT vector. 
For generation of the dominant activating, dominant repressing and hormone inducible 
constructs, the enR, the vp16 and the gr domain were amplified (for primers see chapter 3.3.2.1) 
and subcloned into the TOPO vector for sequencing. They were digested with StuI and XhoI and 
cloned into the pCS2+-MT-vector (Figure 9). 
 
Figure 9: Construction of Xenopus Oct G.o.F. variants.  
The pCS2+-MT6 vector was used as expression system. The 6xMT was fused to the N-terminus. vp16, 
enR, gr domains and oct-cDNAs were cloned into the polylinker. The figure was modified from 
http://sitemaker.umich.edu/dlturner.vectors/home. 
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Figure 10:  All cloned 
constructs are expressed in 
similar amounts in vitro  
In vitro translation was verified by 
western blot via the anti-myc-tag-
antibody 9E10 (1:100). Western 
Blot analysis indicates that all 
generated plasmids are expressed 
in comparable amounts in vitro. 
Numbers in brackets indicate the 
estimated molecular weight (kDa). 
MT-proteins migrate slower than 
according their estimated size. 
 
 
 
 
4.2 Verification of protein overexpression in vitro and in vivo 
4.2.1 Cloned Oct variants accumulate in comparable amounts in vitro 
In toto, 15 constructs were generated. To test the protein expression in vitro, a coupled 
transcription/translation reaction assay with reticulocyte lysates (TNT) was used. The generated 
proteins were resolved on SDS-polyacrylamide gels and were analyzed by western blot using the 
anti-myc-tag-antibody (Figure 10). Protein bands migrated slower than according to their 
estimated size. This is a known phenomenon for MT-proteins. Comparison of the Oct protein 
bands revealed that MT-Oct60 (57kDa) shows the highest mobility, whereas MT-Oct91 (60kDa) 
shows the lowest one (Figure 10, band 4a, 5b, 6c). Within the expression domains, the VP16-
domain (9,5kDa) migrates fastest, followed by the GR-domain (28kDa). The EnR-domain (32kDa) 
showed the lowest mobility (Figure 10, band 1a, 2b, 3c). Comparison of protein bands of Oct25, 
Oct60 and Oct91 shows similar intensities, indicating that their expressed amounts are 
comparable in vitro (Figure 10, band 4a, 5b, 6c). Double bands were observed in the MT-Oct60 
and the MT-EnR-Oct60 bands (Figure 10, band 5b, 9c). Their appearance is most likely due to 
degradation processes or variations in the number of transcribed myc-tags, as it was reported 
before.  
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Figure 11: Oct25, Oct60 and Oct91 are 
enriched in different amounts in vivo  
A) 300pg or 900pg of the indicated mRNA were 
injected into the animal pole of both blastomeres 
at two cell stage. Each lane shows protein extracts 
from one embryo equivalent detected with the anti-
myc-tag-antibody 9E10 (1:100). TNTs are shown 
for comparison of size. Comparison of protein 
bands indicates that Oct91 protein accumulates in 
highest, Oct25 in medium and Oct60 in least 
amounts. 
B) Comparison of protein expression from RNA 
versus DNA. TNTs with 1µg of the indicated RNA 
or DNA were performed. Comparison of protein 
expression reveals that both, RNA and DNA are 
expressed in similar amounts in vitro.    
 
4.2.2 Ectopic Oct25, Oct60 and Oct91 accumulate in different amounts in vivo  
In Xenopus laevis embryos three Oct4 homologs – Oct25, Oct60 and Oct91- are known that have 
different temporal expression profiles. To which degree their functions are overlapping has not 
been shown, yet. The different temporal expression profiles might suggest a difference in function 
between the three Xenopus Oct proteins. 
Considering that the combination of all three Xenopus Oct homologs might mimic the mouse 
Oct4 function best, an equimolar mix of all three constructs was used for the following 
experiments. Embryos were injected with an oct-wt- (consisting of oct25, oct60 and oct91), an 
enR- (consisting of enR-oct25, enR-oct60 and enR-oct91) or a vp16-mix (consisting of vp16-
oct25, vp16-oct60 and vp16-oct91). Embryos were injected into both blastomeres at two-cell 
stage. Surprisingly, western blot analysis of protein expression from embryos injected with the 
oct-wt-mix did not show a homogenous accumulation of the three Xenopus Oct proteins (data not 
shown). Only Oct91 protein was detectable. Consequently, oct25, oct60 and oct91 were injected 
separately. Western blot analysis revealed that the three Oct proteins are present at different 
amounts in vivo (Figure 11, A). Oct91 accumulates in highest levels, Oct25 in medium levels 
while Oct60 is hardly detectable. To test whether this might be a RNA specific effect mediated by 
RNA instability, a TNT was performed with RNA in comparison to DNA (Figure 11, B). The 
experiments showed that in vitro DNA as well as RNA results in comparable protein levels. In 
conclusion, the stability of the RNAs and the efficiency of transcription and translation of the 
tested RNAs seem to be comparable in vitro, but not in vivo.            
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To find out whether the observed differences in protein amounts are time dependent, Oct25, 
Oct60 and Oct91 protein expression was examined at three different developmental stages – NF 
7, NF 9 and NF 11 (Figure 12). The results indicate that unequal accumulation is not a time 
dependent effect. At each examined point in time Oct91 proteins are detectable at highest 
amounts. Western blot analyses of mix injections confirm the unequal enrichment of the three 
Oct-proteins at each examined point of time.  
 
      
 
 
The unequal abundance made it impossible to predict whether observed phenotypes were 
produced by all three Oct-proteins or whether the expression of Oct91 was dominant so that 
phenotypic changes resulted exclusively from Oct91 function. This might have been particularly 
true for Oct60, which appeared to be very unstable, and therefore, might have been outcompeted 
by Oct25 and Oct91. In consideration of these results the mixing injections were stopped.  
 
4.2.3 Injection of oct60, enR-oct60 and vp16-oct60 mRNA results in comparable 
protein levels in vivo 
Oct60 is one of the earliest genes to be transcribed in oocyte development (Whitfield, Heasman 
et al. 1993). Oct60 becomes downregulated during gastrulation, when Oct25 and Oct91 are 
beginning to be expressed. Its expression profile distinguishes Oct60 from the other Xenopus 
Oct4 homologs. Oct60 expression correlates with stages of pluripotency and expression ceases 
when pluripotency is lost. Its expression profile is most consistent with the expression profile of 
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Figure 12: Unequal in vivo 
protein accumulation can be 
observed at different points of time 
in development 
Embryos were injected with 300pg of the 
indicated RNA into the animal hemisphere. 
Embryos, injected with the “Oct-mix”, were 
injected with 300pg of each of the tree oct-
RNAs. Protein expression was analyzed at 
three different points in time (NF 7, NF9 
and NF11) via western blotting. Each lane 
contains proteins from one embryo 
equivalent that were detected via anti-myc-
tag-antibody 9E10 (1:100). At each of the 
examined points in time Oct91 is detected 
in highest, Oct25 in medium and Oct60 
protein in lowest amounts.  
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Oct4. This makes Oct60 exceptionally interesting for further research concerning its function. 
Therefore, I decided to focus on Oct60. 
To find out whether Oct60 and its G.o.F. variants accumulate in comparable amounts in vivo, 
embryos were injected with 900pg/E of oct60, vp16-oct60 or enR-oct60 into both blastomeres at 
two-cell stage. Proteins from embryos NF 15 were separated via an SDS-gel. Western blot 
analysis displayed that all three proteins are present in comparable amounts in vivo (Figure 13). 
 
4.3 Transcriptional activities of wildtype Oct60 and its fusion 
proteins  
It was shown by previous work that murine Oct4 acts in vivo as a transcriptional activator as well 
as a transcriptional repressor (Babaie, Herwig et al. 2007). Little is known about the function of 
Xenopus Oct60. We tested the Oct60 wildtype and its gain of function variants in a transient 
luciferase reporter assay with two artificial Oct4 sensitive promoters (Figure 14).   
 
The more promoter is a palindromic Oct recognition element (ATGCATATGCAT) that mediates 
assembly of stable Oct homodimers and heterodimers leading to strong transcriptional activation 
by mammalian Oct proteins. When binding to the more promoter, the POUS and POUHD domains 
of two different Oct molecules make contact with each half-site (Tomilin, Reményi et al. 2000).  
The 6w enhancer contains 6 copies of a natural octamer binding motif from the mouse Ig heavy 
chain gene enhancer (Botquin, Hess et al. 1998; Tomilin, Reményi et al. 2000). The more 
promoter as well as the 6w enhancer are linked to the luciferase reporter gene, which provides a 
quantitative readout for the transactivating activities of the Oct60 protein variants. As a control, a 
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Figure 13: Oct60, EnR-oct60 and VP16-oct60 
proteins are detectable in comparable amounts in 
vivo  
Embryos were injected with 450pg, 900pg or 1200pg of mRNA 
into the animal hemisphere as indicated. Each lane shows 
purified proteins from one embryo equivalent NF15. Proteins 
were detected with anti-myc-tag-antibodies 9E10 (1:100). 
Western blot analysis shows that Oct60, EnR-Oct60 and VP16-
Oct60 are expressed in comparable amounts in vivo. 
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plasmid containing the renilla gene is coinjected. To find out to which degree the luciferase gene 
is activated, the firefly/renilla coefficients are calculated. 
 
Embryos were injected with Oct60 wildtype or its gain of function variants (900pg of MT6-oct60, 
MT6-vp16-oct60, MT6-enR-oct60 or gfp mRNA (control)) in combination with the more or 6w 
reporter plasmid (100pg) and a plasmid containing the renilla cDNA (100pg).  
Using the more promoter, injection of oct60 resulted in 35-fold stronger activation of the reporter 
plasmid compared to the basal activity in gfp injected control embryos. In vp16-oct60 injected 
embryos a 730-fold stronger activation compared to the control embryos was observed. enR-
oct60 injection resulted in an 2.42-fold repression compared to basal activity (Figure  14, A).  The 
same set up was performed using the 6w instead of the more promoter (data not shown). 
Although activation rates were lower with this promoter similar results were obtained. Oct60 
resulted in 2,8-fold and VP16-Oct60 induced 57-fold activation. As in the previous assay, enR-
Oct60 injection yielded a 2-fold repression compared to gfp injected embryos. This experiment 
was performed three times on the more promoter with comparable results. 
 
The repressing function of EnR-Oct60 was relatively low, compared to the strong activation 
observed in VP16-Oct60 injected embryos. One problem was the relatively low basal activity of 
the more and 6w promoters leading to difficulties in visualizing a possible repression by EnR-
Oct60. For a better demonstration of the repressing function of EnR-Oct60, we decided to 
perform a competition assay. Therefore embryos were injected with a mRNA mix, consisting of 
vp16-oct60 and different concentrations of enR-oct60. If EnR-Oct60 really has a repressive 
effect, activation rates induced by VP16-Oct60 should decrease the more enR-oct60 is 
coinjected. The luciferase assay was performed using embryos injected with 200pg vp16-oct60 
mRNA in combination with increasing dosages of enR-oct60 mRNA. Additionally, activation rates 
were measured after injecting 1000pg of enR-oct60 mRNA or 200pg of vp16-oct60 mRNA. This 
experiment was also performed using the more promoter (Figure 14, B). 200pg of vp16-oct60 
alone resulted in 182-fold activation whereas 1000pg of enR-oct60 led to 2,4-fold repression. 
Coinjection of 200pg of vp16-oct60 with 200pg, 500pg or 1000pg of enR-oct60 mRNA showed 
decreasing activation rates of 12-fold, 6-fold and 1,2-fold, respectively. Therefore, EnR-Oct60 
was able to repress the strong activation induced by VP16-Oct60 almost up to basal activity. 
These results confirm that EnR-Oct60 functions as a repressing transcription factor variant.  
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Figure 14:          Transactivating activities of Oct60 G.o.F. protein variants  
Luciferase assay showing the activating and repressing functions of Oct60 and its G.o.F. variants in vivo. 
The more and the 6w promoters were used as modified palindromic Oct factor recognition elements. 
Embryos were injected into the animal hemisphere of both blastomeres with 900pg of oct mRNA as 
indicated, 100pg of the reporter plasmid and 100pg of a plasmid containing the renilla cDNA.  
A) The luciferase assay, using the more promoter, shows a 35-fold activation by injected oct60 mRNA and 
a 730-fold upregulation by vp16-oct60 mRNA compared to control embryos. EnR-oct60 resulted in 2,4-fold 
repression. 
B) The competition assay was performed on embryos that were injected with 1000pg enR-Oct60 mRNA, 
200pg vp16-oct60 or 200pg of vp16-oct60 mRNA in combination with 200, 500 or 1000pg of enR-oct60 
mRNA. The more promoter was used as an Oct factor recognition element. In addition to the indicated oct 
mRNAs, 100pg of the reporter plasmid and 100pg of a renilla containing plasmid were injected into the 
animal hemisphere of both blastomeres. Data indicates that EnR-Oct60 is able to repress the VP-16-Oct60 
mediated activation. 
A 
B 
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In summary it can be stated that Oct60 acts as a transcriptional activator on both, the more as 
well as the 6w promoter. Injection of vp16-oct60 resulted in a more than 20-fold higher activation 
rate compared to oct60. In both cases activation rates of the more promoter were roughly 13-fold 
higher than activation rates of the 6w promoter. Injection of enR-oct60 resulted in a 2.42-fold 
repression of the more promoter and a 2-fold repression of the 6w promoter. In this way we were 
able to clearly demonstrate the repressing function of enR-Oct60 in a titration assay with VP16-
Oct60 performed with the more promoter. 
Oct60 acts as an activator on both promoters. VP16-Oct60 and enR-Oct60 show the expected 
activating/repressing functions in vivo. It can be concluded that the promoter responses of the 6w 
and more promoters are specific according to different variants of Oct60. 
 
 
4.4 Phenotypic changes caused by injection of oct60 constructs  
4.4.1 Oct60 and its G.o.F. variants impair blastopore closure 
Next, effects of Oct60 on early embryogenesis were investigated by overexpression studies of 
oct60 and its G.o.F. variants.   
As it was described for Oct4 before, Oct60 was able to activate the more as well as the 6w 
promoter in the previous experiments (Botquin, Hess et al. 1998; Tomilin, Reményi et al. 2000). 
Nevertheless, also repressing functions were described for Oct4 (Ben-Shushan, Thompson et al. 
1998; Babaie, Herwig et al. 2007). To gain further insights into the in vivo function of Oct60, 
phenotypes produced by overexpression of Oct60 and its dominant activating and repressing 
forms were compared.  
 
Embryos were injected with 450pg of oct60, enR-oct60 and vp16-oct60, respectively, into the 
animal hemisphere at two-cell stage into one blastomere. Injection into the animal hemisphere 
results in protein overexpression in parts of the embryo that contain multipotent precursor cells 
and express Oct proteins. By injecting only one cell at two-cell stage, mainly one half of the body 
is affected by the overexpression leaving the “wildtype body-half” as an endogenous “un-injected” 
control. To tag which body half was manipulated, Alexa dextrane was coinjected. Additionally, 
control embryos were injected with 450pg gfp to distinguish Oct specific phenotypic changes from 
effects produced by the technique. 
 
During the time of germ layer induction, until NF9, embryos injected with Oct60 and its G.o.F. 
variants showed no apparent abnormalities compared to controls. At gastrula stage 10, 
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blastopore formation begins at the exterior of the embryo. The first indentation is gradually 
evolving to form a complete circle - the line of invagination. Coordinated movements transform 
the blastula into a multilayered embryo with head, trunk and tail rudiments.  
During the process of gastrulation, all embryos injected with oct60 or its gain of function variants 
showed problems in blastopore formation. In the majority of embryos, this resulted in incomplete 
blastopore closure forming mushroom like structures by non-migrating cells (data not shown). 
Blastopore closure defects were most pronounced in embryos that were injected with vp16-oct60. 
More than 50% of these embryos died around stage 11. Therefore, it was necessary to reduce 
the injected vp16-oct60 mRNA dose from 450pg/E to 150pg/E, if phenotypic changes in post-
gastrula stages wanted to be observed. This dose reduction resulted in 25% of the embryos 
showing blastopore closure defects instead of 63% when 450pg/E were injected. Injection of 
oct60 affected the blastopore formation in 21%, injection of enR-oct60 in 28% of the embryos. 
The highest non-lethal RNA dose was 600pg for oct60 and enR-oct60 and 400pg for vp16-oct60. 
Higher doses were lethal, with most embryos dying at gastrula stages. In post-neurula stages the 
incomplete blastopore closure led to incomplete closure of the posterior dorsal midline of the 
embryos. 
 
4.4.2 Injected embryos show developmental defects at distinct parts of the body 
Embryos injected with oct60 mRNA showed a severe hyperpigmentation (91%) that most often 
occurred isolated in the head region and was accompanied by enlargement of the injected head 
side in 68% of all cases (Table 2, Figure 15, row 3,4). Enlargement of the head as well as the 
hyperpigmentation appeared most pronounced around stage 26. 24% of the embryos were 
additionally affected in the trunk region. Hyperpigmentation was transient in most parts. At stage 
33, the hyperpigmentation was of slightly reduced intensity, whereas around stage 40 it had 
almost completely disappeared.  
In contrast to control embryos with entirely black eyes and nearly closed choroids fissures, eye 
development was severely impaired by Oct60 overexpression in 71% of the embryos. Less than 
30% of the embryos showed normal eye formation. Most embryos showed no pigmented retinal 
structure and no visible protrusion of the eye vesicle at stage 33. This seemed to be rather due to 
a delay in development than to an absence of the eye anlage.  At stage 40, incomplete eye 
formation was visible that presented in the majority as partially pigmented optic cups. The degree 
of the eye pigmentation seemed to be almost normal compared to control embryos. However, the 
retinal ring did not seem to be fully developed in form. If present, the size of the optic vesicle 
seemed normal at the injected side. Also the lens formation seemed to be strongly impaired. The 
degree of impairment was reaching from a reduction in size to almost not detectable lens 
structures. 
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Overexpression of EnR-Oct60 induced hyperpigmentation in 88% of the embryos. This 
phenotype however differed from the Oct60 phenotype in localization and pattern (Table 2, Figure 
15, row 5,6). EnR-Oct60 affected the trunk region in 88% whereas the head region was only 
affected in 29%. In contrast, in oct60 injected embryos the head region was predominantly 
affected in 91%. These embryos showed hyperpigmentation combined with an enlargement of 
the affected side of the head.  The hyperpigmentation produced by Oct60 was uniformly spread 
over the body. In contrast to this, the hyperpigmentation produced by EnR-Oct60 appeared 
localized, restricted and protruding. Hyperpigmentation induced by overexpression of enR-Oct60 
did not evenly affect the head region as it was observed in oct60 injected embryos. Instead, 
hyperpigmentation was locally enriched, resembling a spot or line.  
 
Additionally, hyperpigmentation in enR-oct60 injected embryos was accompanied by bulge 
formation in more than 80%. These bulges occurred in hyperpigmented areas only, ranging in 
shape from “tentacle like” to “double axis” like structures. Bulge formation varied in size and 
position. Prominence of bulge formation differs, ranging from only slightly elevated 
hyperpigmented areas to vast outgrowth mimicking a secondary body axis. Bulge formation was 
scored at stage 21-24 at its maximum extensions. At stage 40, the hyperpigmentation and the 
outgrowth were partially retained but did not disappear completely in most cases. The outgrowth 
became less prominent and the hyper-pigmented areas were severely reduced in size and 
intensity.  
Embryos injected with enR-oct60 showed protruding optic vesicles at stage 33. In most cases no 
pigmented retinal structures were observed. At stage 40, 68% of the injected embryos showed 
defects in retinal formation indicated by reduced pigmentation of the retina. Additionally, the optic 
vesicle was reduced in size in about one third of the embryos. Beside the impaired formation of 
the retinal pigment epithelium, lens formation was disturbed. 
 
Overexpression of VP16-Oct60 disturbed predominantly the formation of the head region (Table 
2, Figure 15, row 7,8). In 96%, an enlargement of the injected side of the head was observed at 
stage 24.  Around stage 26, no optic vesicle had formed visibly on the injected side. In 96%, 
impaired eye formation was observed on the injected side of the head at stage 33. Neither a 
protrusion of the optic vesicle nor a pigmentation of retinal structures was visible. At all points of 
time, the neural defects were more prominent in vp16-oct60 injected embryos than in oct60 or 
enR-oct60 injected embryos. At stage 40, about one third of the embryos was still showing 
neither a protrusion of the optic vesicle nor a pigmentation of retinal structures. One third of the 
embryos developed eyes that were severely reduced in size and pigmentation. The rest of the 
embryos showed mildly impaired eyes. Additionally, all embryos that were injected with vp16-
oct60 showed reduced formation of the dorsal fin at stage 33. 
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In control embryos, melanophores appear for the first time dorsally on the head at stage 33/34. 
Melanophores also arrange on the pronephros and in a horizontal row along the trunk, beginning 
ventrally at the pronephros along the axial musculature. Melanophores, visible in control-injected 
embryos at stage 33, were absent in most embryos that were injected with Oct60 and its gain of 
function variants. This indicates a delay in development since they developed partially until stage 
40. Cement gland, gut structures as well as proctodeum formation appeared to be normal in all 
injected embryos. 
 
Phenotypes Control Oct60 EnR-Oct60 VP16-Oct60 
(450pg/E) 
VP16-Oct60 
(150pg/E) 
Gastrulation defects  
(NF 11) 
11/83 (3) 
13% 
21/98 (3) 
21% 
29/103 (3) 
28% 
29/46 (3)    
63% 
19/75 (3)       
25% 
Truncated body axis  
(NF 36) 
4/43 (2) 
9% 
27/56 (2)  
48% 
38/53 (2)  
66% 
11/11(2) 
100% 
42/49 (2) 
86% 
Eye defects  
(NF 36) 
0/43 (2) 
0% 
40/56 (2) 
71% 
36/53 (2) 
68% 
11/11 (2) 
100% 
47/49 (2) 
96% 
Bulge formation in the 
trunk region (NF 26) 
0/86 (3) 
0% 
0/78 (3) 
0% 
51/65 (3) 
78% 
0/26 (3) 
0% 
0/54 (3) 
0% 
Thickening of the head 
region (NF 26) 
0/86 (3) 
0% 
69/78 (3) 
88% 
0/65 (3)  
0% 
26/26 (3) 
100% 
48/54 (3) 
89% 
Delayed melanophore 
formation (NF 36) 
0/43 (2) 
0% 
71/78 (2) 
91% 
39/53 (2) 
74% 
11/11 (2) 
100% 
44/49 (2) 
90% 
Hyperpigmentation 
affecting the head   
(NF 26) 
0/86 (3) 
0% 
71/78 (2)  
91% 
 
19/65 (3) 
29% 
22/26 (3) 
85% 
41/54 (3) 
76% 
Hyperpigmentation 
affecting the trunk  
(NF 26) 
0/86 (3) 
0% 
19/78 (2)  
24% 
 
57/65 (3) 
88% 
 
0/26 (3) 
0% 
0/49 (3) 
0% 
Embryos without 
phenotypic changes  
(NF 26) 
80/86 (3) 
93% 
7/78 (3) 
9% 
8/65 (3) 
12% 
0/26 (3) 
0% 
0/49 (3) 
0% 
 
Table 2:        Representative percentages of observed phenotypic changes produced by injection of 
Oct60 and its G.o.F. variants 
Embryos were injected with either 450pg of oct60, enR-oct60 or vp16-oct60 mRNA or 150 pg of vp16-oct60 
mRNA into one blastomere at two cell stage. Control embryos were injected with 450pg of gfp RNA. 
Phenotypic changes observed at different developmental stages (NF11, NF26, NF36) were counted. Total 
numbers and percentages are shown. The numbers in brackets indicate the numbers of experiments from 
which embryos were obtained. 
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Figure 15:          Overexpression of Oct60 and its G.o.F. variants   
Phenotypic changes observed by overexpression of Oct60 and its G.o.F. variants. Embryos were 
injected with either 450pg of oct60 or enR-oct60 mRNA or 150pg of vp16-oct60 mRNA into one 
blastomere at two-cell stage, as indicated. Control embryos were injected with 450pg of gfp RNA. All 
embryos shown here were injected into the left body half. The first row of every condition shows two 
representative embryos at three points in development (NF 26, NF 33, NF 40). The second row shows 
a magnification of the head region. Red arrows indicate pigmented bulges in the head region. Blue 
arrows indicate hyperpigmented bulges at the trunk region and black arrows point to closure defects of 
the retinal pigment epithelium.  
 
4.4.3 Injected embryos develop a shortened, specifically curved body axis  
Overexpression of Oct60 and its G.o.F. variants induced the formation of a shortened body 
axis compared to wild type embryos. This was most pronounced in vp16-oct60 injected 
embryos, of which 86% showed severe truncation. 48% of the oct60 and 66% of the enR-
oct60 injected embryos showed slight reduction in body length (Table 2). In control embryos, 
tail bud formation begins at stage 24. After a slow initial phase, the process of tail bud 
expansion accelerates at stage 28. At stage 36, the tail bud reaches a length of 
approximately one fourth of the body length. Embryos, injected with 450pg of vp16-oct60, 
appeared ventralized and showed severely diminished tail bud formation in more than 60%. 
In these embryos, body length was reduced to 50 to 75% of control embryos (15 embryos 
measured). The severity of this phenotype was dose-dependent. These changes were not as 
severe in enR-oct60 and oct60 injected embryos. In these embryos, body length varied from 
75 to 100% compared to control embryos.  
Injection into both blastomeres resulted in a kink like dorsal flexure in the majority of 
embryos. This phenomenon also occurred in about 5-10% of embryos that were injected into 
one blastomere. 
 
Control injected embryos responded to touch stimulation with muscle contraction from stage 
24 on. At stage 26, embryos injected with oct60 and its gain of function variants showed no 
or strongly impaired movements in reaction to stimulation with tweezers. At stage 36, also 
oct60 and enR-oct60 injected embryos reacted adequately to stimuli. Embryos, injected with 
450pg of vp16-oct60, were most severely affected. Their truncation hindered them in 
performing normal movements, like swimming. Upon stimuli, they reacted with cramp like, 
rapid motions. 
 
Beside the abnormalities described above, embryos, injected into one cell at two-cell stage, 
showed a specific curvature (Figure 16). The curvature was counted at stage 24. Three 
hours prior to enumeration, the remaining vitellin membranes were removed. This allowed 
the embryos to stretch and straighten from their constricted position within the vitellin 
membrane.  
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More than 50% of the embryos, injected with oct60 mRNA, showed a curvature directed 
towards the injected side. Embryos that were injected with vp16-oct60 RNA also showed a 
curvature to the injected side in more than 70%. The curvature showed its maximum in the 
anterior region of the embryo. In contrast to this, enR-oct60 injected embryos curved to the 
non-injected side in more than 65%. In these cases, the maximum of the curvature was in 
the trunk region. Control injected embryos were equally curved to the injected or non-injected 
side, whereas the majority of uninjected embryos was not curved (more than 70%).  This 
curvature disappeared partially in most of the cases as embryos developed. It was most 
prominent around NF 24-26. 
In summary, it can be stated that embryos, injected with oct60 and its G.o.F. variants, show 
defects at distinct parts of the body. Oct60 and VP16-Oct60 seem to affect predominantly the 
head region whereas enR-Oct60 injected embryos show also an affection of the trunk region. 
Most prominent changes include hyperpigmentation, disturbance of the formation of the head 
and a specific curvature of the main body axis. Phenotypic changes are transient and 
improve during development. Some of these defects like the inappropriate eye and 
melanophore formation seem to reflect developmental retardation. 
 
Figure 16:       Oct60 and its G.o.F variants cause curvature of the main body axis 
Embryos were injected with 450pg of mRNA into one blastomere at two cell stage, as indicated. The 
curvature was counted at stage 24. Three hours prior to enumeration the remaining vitellin 
membranes were removed. The majority of embryos injected with oct60 was curved to the injected 
side (more than 50%). The same phenomenon was observed in more than 70% of vp16-oct60 injected 
embryos. In contrast, overexpression of EnR-Oct60 led to a curvature to the non-injected side in more 
than 65%. Uninjected control embryos were mainly not curved at this stage of development. Embryos 
that were injected with 450pg of gfp mRNA were curved to the injected or non-injected side in similar 
percentages.   
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4.5 Molecular analysis of interference phenotypes 
Malformation in the head region, pigmentation defects, trunk outgrowth and a curved body 
axis were the most prominent phenotypic changes. To further investigate the nature of the 
observed phenotypes, in situ hybridizations were performed.  
Whole mount RNA in situ hybridization is used for detection of localized, specific mRNAs in 
fixed embryos. Compared to other techniques for analyzing gene expression like RT-PCR its 
advantage is the additional spatial resolution up to single cell level. 
 
Embryos were injected with 450pg of oct60, enR-oct60 or 150pg of vp16-oct60 mRNA, 
respectively into the animal region of one cell at two-cell stage. 100pg of lacZ mRNA were 
coinjected to detect the injected region. Control embryos were injected with 100pg of lacZ 
RNA. Early gastrula stage embryos (NF 10,5-11,5) and tadpole stages (NF 28) were used for 
staining. 
4.5.1 Neuroectodermal interference 
Head defects, observed most prominently in vp16-oct60 and oct60 injected embryos, and 
hyperpigmentation, observed in enR-oct60 and oct60 injected embryos, indicate disturbance 
of neuroectodermal tissues. To analyze the gene expression pattern of the late 
neuroectodermal marker n-ß-tubulin, in situ hybridizations were performed on embryos stage 
28 (Figure 17). This experiment was repeated three times with comparable results on 
embryos from different injection rounds. 
Injection of Oct60 and its G.o.F. variants resulted in severe disturbance of the n-ß-tubulin 
expression pattern. In control embryos, n-ß-tubulin expressing domains, placodes, the eye 
region, the brain and the notochord were clearly defined. In embryos, injected with Oct60 and 
its G.o.F. variants, the n-ß-tubulin expressing domain was broadened. This was most 
prominent in vp16-oct60 injected embryos. The different anatomic structures were hardly 
distinguishable (Figure 17, column 3). Epibranchial placodes were not detectable on the 
injected sides. Especially in enR-oct60 injected embryos, ectopic n-ß-tubulin expressing cells 
were detectable towards the trunk region. The n-ß-tubulin staining seemed to almost affect 
the whole broadened head domain in oct60 and vp-16-oct60 injected embryos. Ectopic n-ß-
tubulin expressing cells were found in the vicinity of the trunk outgrowth of enR-oct60 
injected embryos but could not be found within the actual outgrowth. Interestingly, lacZ 
positive cells were concentrated in these trunk bulges (Figure 17, row 5, column 5). 
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4.5.2 Mesodermal interference 
The specifically curved main body axis, produced by injection of oct60 and its G.o.F. 
variants, suggests alteration in the process of convergence-extension. To test whether this 
results from changes in mesoderm expression and to figure out whether the observed bulges 
in the enR-oct60 injected embryos were formed by mesodermal tissue, we analyzed the 
expression of the early mesodermal marker xbra and the late mesodermal marker cardiac 
actin (Figure 18 A,B). Xbra is a T-box transcription factor that is expressed from stage 10 on 
until tadpole stage. Xbra can be used as a pan-mesodermal marker for in situ hybridization. 
Cardiac actin is expressed in both, the cardiac and skeletal muscle, in later stages of 
development.  
In situ hybridization for xbra revealed a disturbed expression pattern produced by Oct60 
and its G.o.F. variants. In situ hybridizations were repeated 4 times with comparable results 
on embryos from different injection rounds. Embryos, injected with oct60, enR-oct60 or vp16-
oct60, showed a disruption of the wt xbra ring (Figure 18, A). As shown by lacZ lineage 
tracing, xbra mRNA was ablated only when the injected mRNAs reached into the 
suprablastoporal region, where xbra is induced. This suggested a cell-autonomous inhibition 
of Xbra transcription by the injected Oct60 proteins. Additionally, in 2 of 4 in situ 
hybridizations ectopic xbra expression was observed in addition to the disrupted wt 
expression in oct60 and enR-Oct60 injected embryos. The ectopic xbra stain was located 
towards the animal region (data not shown). In vp16-oct60 injected embryos, no ectopic xbra 
expression was observed, but a severe disruption of the xbra ring was visible.  
In situ hybridization for cardiac actin showed a disruption of somite formation by Oct60 
and its G.o.F. variants (Figure 18, B). Most severe effects were seen in embryos injected 
with enR-Oct60 and vp-16-Oct60. Interestingly predominantly the anterior somites were 
affected. Posterior somites showed an almost normal development. Anterior somites 
featured reduced cardiac actin expression as well as disturbed pattern formation.  
 
 
 
Figure 17:      The expression pattern of the neural marker n-ß-tubulin is strongly 
disturbed by overexpression of Oct60 and its G.o.F. variants 
Embryos were injected with 450pg of oct60 or enR-oct60 or 150pg of vp16-oct60 mRNA respectively. 
Additionally, 100pg of lacZ mRNA were injected. Control embryos were injected with 100pg of lacZ 
mRNA only. Embryos were fixed at stage 28 and stained for n-ß-tubulin and lacZ. For each injected 
mRNA, pictures of one representative embryo are shown.  Column 1 and 2 show and overview of the 
embryo with the upper row in column 2 showing the injected, the lower row showing the non-injected 
body half. Column 3 shows a magnification of the head region. Column 4 shows a cross section as 
indicated in column 3 by the white, dashed lines. The upper picture shows the anterior part, the lower 
picture the posterior part of the embryo. Column 5 shows a magnification of the trunk region. Light 
blue represents lacZ lineage trace, dark blue indicates n-ß-tubulin expression. The model showing 
placode formation was taken from Schlosser and Ahrens (2004). 
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4.5.3 Endodermal interference 
In situ hybridization for the endodermal marker endodermin, performed on embryos stage 26 
and 36 that were injected with oct60 and its G.o.F. variants, showed no changes in the 
expression pattern (data not shown).  
 
 
 
 
Figure 18: Injection of oct60, enR-oct60 and vp16-oct60 leads to disturbed 
development of mesodermal tissues in early embryos 
In situ hybridizations were performed on gastrula stage embryos (NF10) and on tailbud embryos (NF 28) 
that were injected at two-cell stage into one blastomere as indicated. LacZ mRNA was coinjected. The 
lacZ stain indicates the injected region and is visible in light blue. One representative embryo is shown 
for each injected mRNA. 
A) Xbra in situ hybridization shows a disruption of the xbra ring by all injected mRNAs. Row 1 and 2 
show the injected embryo from different angles of view. Row 3 shows cross sections of the same 
embryo, as indicated in row 2 by black dashed lines. 
B) Cardiac actin in situ hybridization indicated that Oct-60 and its G.o.F variants disturb the formation 
of somites (indicated by red arrows). The upper row shows the uninjected body side, the lower row 
shows the injected one. Especially in oct60 and vp16-oct60 injected embryos, hardly any cardiac actin 
staining is visible in the injected area. In enR-oct60 injected embryos a diminished stain is visible.       
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5 Discussion  
Reprogramming of adult cells was first described in 2006, when the group of Shinya 
Yamanaka's team at Kyoto University, Japan, succeeded in inducing pluripotent stem cells 
from mouse fibroblasts (Takahashi and Yamanaka 2006). In 2007, the group of James 
Thomson created induced pluripotent stem cells from adult human cells (Yu, Vodyanik et al. 
2007). Both groups came to the conclusion that two proteins are essential for 
reprogramming: Sox2 and Oct4. Lately, it was shown that Oct4 alone is sufficient to induce 
pluripotent stem cells from adult cells (Kim, Sebastiano et al. 2009). Apparently, adult cells 
are still sensitive to Oct4 expression.  
In mammalian normogenesis, Oct4 expression is extremely well regulated. In early 
development, alterations in the expression level of mouse Oct4 lead to differentiation into 
extra-embryonic tissue or early endoderm (Niwa, Miyazaki et al. 2000).  
Though the importance of Oct function in cell reprogramming and differentiation is evident, 
the molecular mechanisms by which Oct4 affects the pluripotent state and the transition from 
pluripotency to cellular determination is still largely unknown. 
 All the experiments named above were performed in mammals. POU V proteins have also 
been found in multiple amphibians e.g. zebrafish (DrPOU2), axolotl (AmOct4) and Xenopus 
(Frank and Harland 1992; Hinkley, Martin et al. 1992; Whitfield, Heasman et al. 1993; 
Burgess, Reim et al. 2002; Bachvarova, Masi et al. 2004). Nevertheless, the question, 
whether the role of Oct4 in maintaining pluripotency and its ability to reprogram adult cells is 
conserved or mammalian-specific has not been answered yet. In Xenopus laevis, three Oct4 
homologs are known – Oct25, Oct60 and Oct91. The aim of this study was to find out more 
about Oct protein function including their role in maintaining the pluripotent state and their 
influence on cell fate decisions and differentiation in Xenopus laevis early development. By 
cloning dominant activating and dominant repressing Oct constructs for all three Xenopus 
Oct proteins, I obtained important tools for further evaluating and comparing Oct protein 
function.  
  
 
5.1 G.o.F. protein variants 
5.1.1 Studying Oct protein function: advantages of using gain-of-function variants 
It was shown by previous work that mouse Oct4 acts as a transcriptional activator as well as 
a transcriptional repressor in vivo (Babaie, Herwig et al. 2007). Whether Xenopus Oct60 
shares similar trans-activating functions is unknown. To investigate this question, we decided 
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to generate dominant negative and constitutively active transgenes to convert the 
transcriptional gene regulation of Oct transcription factors into dominant-activating and 
dominant-repressing activities.  
 
Classical analysis of protein function is performed by gene mutation studies. This approach 
is subject to restrictions, since gene mutations often implicate early embryonic lethality. 
Moreover, related factors might compensate for mutated genes. Alternative approaches to 
bypass these drawbacks include downregulation of protein expression and overexpression 
studies. Several means can be used for this including wild-type DNA or RNA, antisense RNA 
or morpholino antisense oligonucleotides.  
Furthermore, antimorphs display important tool to investigate transcription factor functions. 
Antimorphs are mutant alleles, which act in the opposite direction to normal alleles. 
Their use offers several advantages compared to overexpression and loss-of-function 
studies. Loss-of-function approaches only reflect the unique contribution of a mutated or 
silenced gene. Especially when looking at the three Oct4 homologs in Xenopus, other Oct 
proteins might compensate, if one Oct protein is deficient. This might result in less severe 
phenotypic changes.  
By comparing phenotypic changes that are produced by overexpression of the wildtype-
protein with dominant-activating and -repressing protein variants, conclusions can be drawn 
with respect to protein function and molecular regulatory networks – if the effect produced by 
injection of wildtype-RNA resembles the activating G.o.F. variant, the wildtype-transcription 
factor must be an activator and vice versa.  
 
5.1.2 Construction of G.o.F. Oct protein variants 
Several general requirements have to be fulfilled when generating G.o.F. constructs: an 
expression system has to be used that assures the transcription of high amounts of 
polyadenylated RNA for injection. After injection, RNA has to be translated efficiently. 
Proteins should be detectable by antibodies to confirm protein expression in vitro as well as 
in vivo. Since antibodies feature different binding activities it is favorable, if all proteins can 
be detected by the same antigenic epitope. Thus, protein expression can be compared most 
accurately.  
We decided to use the pCS2+-MT6 vector, which fulfills the mentioned requirements best. 
The pCS2+-MT6 vector was designed for generating epitope-tagged fusion proteins and 
allows the production of DNA as well as RNA for the injection into Xenopus oocytes (for 
further information, see http://sitemaker.umich.edu/dlturner.vectors/home). 
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Transcription factors regulate transcription of specific genes to control cellular functions. This 
is achieved through binding to target DNA sequences, followed by interactions with 
components of the basal transcriptional machinery. These two capacities can be structurally 
and functionally separated into distinct DNA-binding and effector domains. The DNA-binding 
domain ensures nucleotide sequence-directed localization to target genes. The effector 
domain interacts with one or more components of the basal transcription complex, either 
directly or indirectly via bridging cofactors, to mediate activation or repression of transcription 
(Vickers and Sharrocks 2002; Chandler and Werr 2003). 
Multiple regulatory domains for the generation of G.o.F. protein variants are known. We 
decided to use the VP16 activation domain as well as the Engrailed repression domain.  
The VP16 activation domain from the herpes simplex virus has often been used in Xenopus 
to generate dominant activating protein variants. For example, the homeodomain repressor 
Xoptx2 reduces eye size under VP16 activation (Zuber, Perron et al. 1999) and the Xenopus 
repressor GOOSECOID under VP16 activation upregulates gene expression in the dorsal 
marginal zone and leads to embryos with severe axial defects (Ferreiro, Artinger et al. 1998). 
The Engrailed (EnR) homeodomain protein originates from Drosophila melanogaster and 
plays an important role in organizing the segmented body plan. EnR is an active 
transcriptional repressor (Pownall, Isaacs et al. 1998; Chandler and Werr 2003). Similar to 
the activator domain of the VP16 protein, the EnR effector domain can be fused to 
transcription factors, so that the targeting function of the transcription factor is combined with 
the effector function of the EnR domain. Thus, the transcription factor keeps its targeting 
function, resulting in DNA sequence-specific binding to target genes, but its effect on 
transcription is dominated by the VP16 or EnR effector domain, resulting in either 
transcriptional activation or repression of target genes (Jaynes and O'Farrell 1991).  
We decided to fuse the 6xMT domain to the N-terminus of our G.o.F. variants. C-terminal 
fusion also seems to work but the N-terminal fusion is the most common and best-studied 
way. The vp16 and enR effector domains as well as the gr domain were digested with StuI 
and XhoI, Xenopus-oct-cDNAs were digested XhoI, XbaI. Effector domains were cloned at 
the 5´-end of the Xenopus oct cDNAs into the polylinker (Figure 8,9). 
 
Injection of mRNAs into cleavage-stage embryos generally results in immediate translation. 
Experiments suggest that over the first 24h approximately 50% of injected mRNA stays intact 
(Colman and Drummond 1986). Endogenous Xenopus oct mRNAs are mainly detectable 
until stage 14. Therefore, a prolongation of Oct protein expression can be achieved by 
injecting oct mRNAs. 
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5.2 Oct proteins are detectable in different amounts in vivo 
Work performed by Morrison and Brickman suggests that the ability of mouse Oct4 to 
maintain pluripotency is derived from an ancient POU V function. The three Xenopus Oct 
proteins are able to recue knockdown of Oct4 to various extends. Xenopus Oct-proteins most 
likely play overlapping but distinct roles during embryogenesis (Morrison and Brickman 
2006). We therefore argued that overexpression of all three Xenopus Oct proteins might 
mimic Oct4 function best. Nevertheless, injection of the three Xenopus Oct mRNAs did not 
result in comparable protein amounts in vivo (Figure 11). This finding was in contrary to 
results from in vitro studies, where all three Oct mRNAs were detectable in comparable 
amounts (Figure 10).  Differences in RNA stability were excluded in vitro; nevertheless, this 
cannot exclude different half-lifes in vivo. Regulatory mechanisms like RNAi or binding of 
proteins, which may affect mRNA stability, are unlikely since our synthetic mRNAs lack 
UTRs.  
Xenopus Oct proteins are expressed at different time points in development. Therefore, I 
tested whether differences in protein expression are time-dependent. If the mRNA stability is 
the determining factor, comparable amounts of protein are expected in early development, 
whereas differences in protein amounts should increase in later development. This does not 
seem to be the case. The examination of MT-Oct protein levels revealed that this 
phenomenon is time independent. At each examined point of time MT-Oct91 was detected at 
highest, MT-Oct25 at intermediate, and MT-Oct60 in lowest levels (Figure 12). Still, a 
regulation among the injected Oct-proteins themselves could be a possible explanation. 
Recent experiments performed in our lab indicate that endogenous Oct proteins regulate the 
expression of each other (data not shown). Whether this regulation occurs at the DNA, RNA 
or protein level has not yet been examined. The ultimate reason of the unequal accumulation 
levels remains uncertain. Due to different protein expression levels, we stopped the 
combined injections of all three Xenopus Oct mRNAs and decided to concentrate on Oct60 
alone.  
 
 
5.3 Validation of the biological activities of Oct fusion proteins 
By generating G.o.F. Oct protein variants, heterologous protein domains were fused to wild-
type Xenopus Oct proteins. To confirm, that both, the DNA binding domains of the Oct 
proteins as well as the VP16/enR effector domains function in the expected manner, we   
performed a luciferase assay on two different promoters. With this assay I intended to test 
the activity of MT-Oct60 proteins on these promoters. Both promoters are strongly activated 
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by Oct4 and other mammalian POU proteins, but there is no published data on a possible 
activation by Oct60 (Niwa, Masui et al. 2002; Takebayashi-Suzuki, Arita et al. 2007). DNA- 
binding domains in POU proteins are highly conserved between mammals and Xenopus 
laevis. Nevertheless, sequence identity in the POU-specific- and POU-homeodomains 
comparing Oct60 and Oct4 are lower (57,7%) than between Oct25/Oct91 and Oct4 
(65,3/66%) (Morrison and Brickman 2006). 
 
Reporter gene analysis represents a sensitive tool to study the activity of transcription 
factors. We used a reporter plasmid encoding firefly luciferase that has enzymatic activity, 
placed under the control of transcription factor response elements. If transcription is 
activated, luciferase is expressed, which emits light when a suitable substrate is added. The 
light output can then be quantified using a luminometer and the intensity of light emitted is 
proportional to the level of luciferase expression.  
Two different promoters were tested: the more and the 6w promoter. The more (More 
palindromic Oct1 Responsive Element) promoter is an optimal artificial palindromic Oct 
binding site (ATGCATATGCAT). Several members of the Oct family including Oct4 were 
found to bind cooperatively as homo- and heterodimers to the consensus more (Tomilin, 
Reményi et al. 2000). When binding to the more promoter, the POUS and POUHD domains of 
two different Oct molecules make contacts with each half-site (Tomilin, Reményi et al. 2000).  
The 6w enhancer contains 6 copies of oligonucleotides with a natural octamer binding motif 
from the mouse Ig heavy chain gene enhancer (Botquin, Hess et al. 1998; Tomilin, Reményi 
et al. 2000).  
 
Oct60 by itself was found to be a strong activator of both, the 6w, as well as the more 
promoter. Injection of vp16-oct60 mRNA resulted in an even stronger activation, which was 
more than 20-fold stronger than Oct60 mediated activation (Figure 14 A). Since the basal 
activity of the more and the 6w promoter, which probably includes activation by endogenous 
Oct proteins, was low, the activity of EnR-Oct60 could not be visualized. However, 
coinjection of enR-oct60 with vp16-oct60 resulted in a strong, EnR-Oct60 dependent 
repression on both promoters (Figure 14 B).  
Based on the reporter assays, native Xenopus Oct60 acts, similar to Oct4, as a 
transcriptional activator with regards to its direct binding to the promoters via the octamer 
motif. EnR-Oct60 and VP16-Oct60 are able to bind to both promoters, indicating that the 
fused effector domains do not disturb DNA binding function. Both effector domains act in a 
dominant fashion and show the expected transcriptional activities. 
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5.4 Embryonic phenotypes 
5.4.1 Penetrance and expressivity  
Phenotypes, observed by injection of oct60 and its G.o.F. variants, showed a range of 
severity within each injection round as well as varieties in penetrance and expressivity, when 
comparing different injection rounds. 
  
A wider range in expressivity was observed in enR-oct60 and vp16-oct60 injected embryos 
than in embryos that were injected with oct60. To give an example - changes in eye 
development reached in vp16-oct60 injected embryos from absent eyes to normal appearing 
eyes that where slightly retarded in development. Oct60 injected embryos showed almost the 
same degree of malformation comparing embryos from one injection round. One possible 
explanation for this are differences in the location and depth of penetration of the injection 
needle, resulting in different allocation of the mRNA so that various parts of the embryo are 
affected to different degrees. Different mRNA distributions were also observed when 
embryos were stained for lacZ. 
 
Additionally, differences in expressivity and penetrance were observed comparing different 
injection rounds. This is most likely due to variations in the injection dosage. When injecting 
the embryos, the needle is manually broken and calibrated through visual examination. This 
might add up to small errors when measuring the concentration of RNA. From studies with 
Oct4, it is known that the observed phenotypic changes are highly dose dependent (Niwa, 
Miyazaki et al. 2000).  
 
Vp16-oct60 injected embryos were affected most severely, especially by gastrulation defects, 
head defects and defects in epithelial layers. This made it necessary to reduce the injected 
mRNA dose when post-gastrula stages should be obtained. One possible explanation is the 
massive activation of target genes, which was more than 20fold higher than the activation 
observed by Oct60 in the luciferase assay. Even when reducing the injected dose from 
450pg to 150pg, the percentage of embryos surviving until post-gastrula stages was lower 
than in oct60 and enR-oct60 injected groups. 
 
5.4.2 Oct60 and VP16-Oct60 produce similar phenotypic changes  
Phenotypic changes affected predominantly the head and eye region in oct60 and vp16-
oct60 injected embryos. EnR-oct60 injected embryos revealed a bulge like thickening within 
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the trunk region. Additionally, a specific curvature of the main body axis was observed 
(Figure 16). Comparing the different Oct60 variants, the phenotype produced by Oct60 
resembles more the one produced by injection of vp16-oct60 than the one produced by EnR-
Oct60 – though they are not identical. Both, oct60 and vp16-oct60 injected embryos were 
curved predominantly towards the injected body half and phenotypic changes affected 
especially the head region, resulting in thickening of the head. Hyperpigmentation was more 
prominent in oct60 injected embryos, affecting a large proportion of the injected body half. 
Also enR-oct60 injected embryos displayed defects in head development that were less 
severe. The most prominent findings in these embryos were hyperpigmented bulge-like 
outgrowths in the trunk regions (Table 2, Figure 15). 
In summary, the injected constructs produced different phenotypes, with oct60 and vp16-
oct60 injected embryos sharing multiple characteristics. 
 
5.4.3 Perturbed formation of anterior structures 
As outlined above, injection of oct60 and its neomorphic protein variants resulted in severe 
defects of the head- and eye formation. Affection of the retinal pigment epithelium as well as 
the lens was macroscopically detectable. Although, the same structures were affected by all 
injected mRNAs, the morphology of eye defects differed in appearance and shape. Inhibition 
of lens formation was most pronounced in embryos that were injected with oct60. The only 
structure that was macroscopically detectable was the dorsal retinal structure. In enR-oct60 
injected embryos, eye formation was less disrupted. Noticeable was a microphthalmia and 
reduction of the retinal pigmentation in these embryos. Additionally, the optic fissure was not 
clearly detectable and often seemed to be positioned more towards the cement gland 
compared to control embryos. Vp16-oct60 injected embryos showed no detectable eye 
structures or microphthalmia in very high percentages. 
A bulge-like thickening of the head was observed in oct60 and vp16-oct60 injected embryos. 
In contrast to vp16-oct60 injected embryos, head bulges in oct60 injected embryos were 
strongly hyperpigmented. These bulges were most prominent around stages 24-26, and 
were strongly reduced with regard to size and pigmentation following differentiation.  
 
Other POU proteins are known to perturb development of neural and epidermal structures 
when misexpressed: XlPOU2, a member of the class III POU domain family, is expressed 
initially in the Spemann’s organizer and later in discrete regions of the developing nervous 
system in Xenopus laevis. XlPOU2 is a target gene of the neural inducer noggin and plays 
an important role in neural determination. XlPOU2 is capable of inducing neural specific 
genes such as ncam or n-ß-tubulin. Misexpression of XlPOU2 in the epidermis causes a 
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direct switch in cell fate from an epidermal to a neuronal phenotype (Witta, Agarwal et al. 
1995; Matsuo-Takasaki, Lim et al. 1999). Similar to XLPOU2, overexpression of Oct60 
resulted in ectopic expression of the neural marker n-ß-tubulin. Whether these findings result 
from a common mechanism in inducing neural gene expression remains uncertain and is 
subject to further research. 
 
5.4.4 Pigmentation defects 
Oct60 and enR-oct60 injected embryos displayed severe hyperpigmentation at distinct parts 
of the body. Injection of oct60 predominantly resulted in hyperpigmentation affecting the 
head whereas injection of enR-oct60 produced hyperpigmented bulges at the trunk region. 
Hyperpigmentation was visible earlier in development than the endogenous pigmentation 
indicating premature production of melanin. In contrast to the premature formation of ectopic 
pigmentation, the normal pigmentation was retarded in embryos injected with oct60 and its 
G.o.F. variants. At stage 33, when control embryos displayed melanophores, embryos 
injected with oct60 and its G.o.F. variants showed no normal pigmentation. At stage 40, the 
pigmentation had almost normalized indicating that the absence of pigmentation at stage 33 
represented a developmental delay.   
Interestingly, the ectopic hyperpigmentation, especially the one on the outgrowth of enR-
oct60 injected embryos, did not disappear when embryos were bleached after in situ 
hybridizations. This made it difficult to judge the staining of in situ hybridizations in the 
affected body parts. Preliminary experiments, performing cross-sections through the trunk 
outgrowth, were suggestive of a thickened epidermis in this region. Further experiments have 
to be carried out to confirm these findings. Nevertheless, a thickened epidermis could explain 
the experienced bleaching problems. Hyperpigmentation has never been observed in animal 
caps, to my knowledge. 
 
While the epidermis of the frog tadpole is uniformly pigmented, a few organs stand out by a 
higher concentration of pigment. These include the cement gland, the hatching gland, and 
the dorsal region (roof plate) of the neural tube. In vertebrates, melanocytes are derived from 
multipotent neural crest cells (Dushane 1934). In amphibians, three types of pigment cells - 
black melanophores, yellow xanthophores, and silvery iridophores - differentiate from neural 
crest cells (Epperlein, Löfberg et al. 1996). On completion of neurulation, the neural crest lies 
dorsal to the neural tube and immediately below the epidermis. Transparent melanoblasts 
migrate from this position to their definitive locations in the embryo, where they differentiate 
and give rise to a species-specific larval pigment pattern (Macmillan 1976). 
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Therefore, the black shape of the observed hyperpigmentation might be either due to an 
ectopic formation of melanin-producing cells, an inhibition of migration or a local 
overproduction of melanin. However, the vast increase in pigmented areas in the injected 
embryos makes it unlikely that they are caused only by inhibition of neural crest cell 
migration. Degrees of survival, proliferation, and differentiation of melanophores are other 
features that have to be considered. Ectopic-pigmented cells displayed a punctuated shape. 
Therefore, they differ from normal melanophores, which are of dendritic nature.  
 
Ectopic pigmentation was described previously in large scale functional screens (Grammer, 
Liu et al. 2000; Chen, Voigt et al. 2005) in conjunction with a variety of genes including the 
transcription factors ESR6, Slug, Forkhead, Hairy 2B, Sox2, and Sox21 (Deblandre, 
Wettstein et al. 1999), a diacylglycerol binding protein essential for synaptic vesicle 
maturation (Munc13) (Augustin, Rosenmund et al. 1999), a sequence specific regulator of 
pre-mRNA splicing (Tra-2 a) (Tacke, Tohyama et al. 1998), and a zinc-binding protein of 
unknown function (Chp-1) (Brancaccio, Menini et al. 2003).  
Additionally, ectopic expression of the Gli1 transcription factor, a regulator of sonic hedgehog 
signaling, causes ectopic pigmented outgrowth within the trunk region that resembles those 
observed in enR-oct60 injected embryos (Dahmane, Lee et al. 1997). This pathway has been 
implicated in the induction of human cancers. Interestingly, the formation of Gli1-induced 
pigmentation defects seen in Xenopus may be analogous to the formation of human 
melanomas (Dahmane et al., 1997). The above named proteins that are implicated in the 
formation of ectopic pigmentation might serve as starting points for further evaluating the 
molecular mechanism underlying ectopic pigmentation induced by Oct60. 
 
In mouse, ectopic expression of Oct4 in epithelial tissues results in dysplastic growths that 
are dependent on continuous Oct4 expression. Tumors are fully reversible when Oct4 
expression is stopped (Hochedlinger, Yamada et al. 2005). A similar phenomenon was 
observed in enR-oct60 injected embryos – here, the pigmented bulges disappear when the 
injected mRNA decays. Whether hyperpigmentation observed in embryos injected with oct60 
and its G.o.F. variants reflect dysplastic lesions remains uncertain to date.  
   
5.4.5 Bulge formation in the trunk region 
Several attempts have been made to determine the nature of the observed bulges by in situ 
hybridization. Cardiac actin, endodermin and n-ß-tubulin did not stain the bulges, indicating 
that they are not composed of differentiated mesodermal, endodermal or neuronal tissues. 
Staining with the early mesodermal marker xbra was observed in two embryos at stages 14 
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and 26 within the bulges (data not shown). Unfortunately, this observation could not be 
reproduced in further experiments. At NF 24/26, xbra is hardly expressed anymore in the 
embryo (Smith, Price et al. 1991; Tadano, Otani et al. 1993). Thus, ectopic xbra mRNA in 
Oct60 perturbed embryos may represent a rather transient feature of a retarded 
differentiation state. This may explain difficulties in detecting xbra expression in the trunk 
bulges. 
Other possible causes for difficulties in characterizing the underlying tissue might be that the 
bulges consist of disorganized tissue, tissues we did not test for or might be retarded in the 
process of differentiation. One problem was the strong hyperpigmentation affecting the 
region of the bulges that was not reactive to bleaching and therefore made it difficult to 
evaluate any underlying in situ staining. Future studies will attempt to identify the fate and the 
molecular mechanism of the observed pigmented bulges. 
 
5.4.6 Shortened and specifically curved main body axis  
Phenotypic changes produced by injection of oct60 and its gain of function variants included 
a shortened and specifically curved main body axis. Embryos, injected with oct60 and vp16-
oct60, curved mainly to the injected side, whereas injection of enR-oct60 resulted in a 
curvature to the non-injected side (Figure 16). 
In general, a curved anteroposterior body axis forms, when the left and right body axis 
elongate at different rates. This can be caused by different cell proliferation activities or 
different morphogenic activities, in particular convergent extension. 
In the process of convergent extension, cell intercalation is narrowing tissue along one axis 
while elongation occurs along a perpendicular axis by cellular movements (Keller, Davidson 
et al. 2000). Therefore, a curvature towards the injected side is consistent with an inhibition, 
while a curvature away from the injected side is consistent with an increase in convergent 
extension movements on that side. 
Alterations can be produced by quantitative as well as qualitative changes in this process: on 
the one hand, alteration of cell fate can result in up or downregulation of cells that can 
undergo convergent extension. On the other hand, a change in cell behavior can inhibit or 
boost the ability to undergo convergent extension.  
Convergent extension involves multiple cell types. During Xenopus development, the 
presumptive posterior hindbrain and spinal cord undergo convergent extension movements 
in parallel with similar movements that occur in the underlying mesoderm (Keller, Davidson 
et al. 2000; Gilbert 2006). Therefore, a gain or loss of these tissues can result in changed 
extends of convergent extension. This can also be caused by changes in the cell behaviour 
or features like polarity decisions in the tissues mentioned above. Hereby, it is important to 
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keep in mind that convergent extension is not a passive event, but rather an active, 
autonomous morphogenetic process (Keller and Danilchik 1988; Elul and Keller 2000; Keller, 
Davidson et al. 2000). 
Noncanonical Wnt signaling is a common mechanism that controls convergent extension in 
both, mesodermal and neural tissues (Deardorff, Tan et al. 1998; Medina, Reintsch et al. 
2000; Wallingford and Harland 2001). Disruption of Wnt signaling results in changes in the 
process of convergent extension (Wallingford and Harland 2001; Yokota, Kofron et al. 2003). 
Interestingly, mouse Oct4 as well as Xenopus Oct4 homologs were recently describes to 
modulate Wnt/ß-catenin signaling (Abu-Remaileh, Gerson et al. 2010).  
 
The fact that the observed curvature differences dissolve during further development 
indicates that the higher/lower extend of convergent extension can be compensated. This 
can be achieved by active or passive mechanisms: One possible hypothesis is that the 
limited or accelerated degree of convergent extension becomes normal again and 
compensates. Besides this also an increased tension and traction that is due to the curvature 
might act as a stimulus for the shorter side to elongate.  
 
With regard to the shortened body axis, phenotypic changes are most consistent with a 
ventralization of the embryos. Recently published data suggests that this is most likely due to 
inhibition of Wnt/ß-catenin signaling. Interestingly, ventralization was also observed by 
overexpression of mouse Oct4 in Xenopus embryos (Abu-Remaileh, Gerson et al. 2010).  
Therefore, both, the curvature of the body axis as well as the ventralization, could be 
explained by modulation of Wnt signaling. 
 
5.4.7 Transient nature of phenotypic changes  
A common feature of the observed phenotypes was their transient nature. Bulge formation in 
the head as well as in the trunk region diminished in size, hyperpigmentation normalized, the 
curvature of the main body axis became less, eye formation was retarded but eyes became 
visible even though often dysplastic in the process of development and the truncated body 
axis improved gradually. Most phenotypic changes were most distinctive around stage 24-28 
and improved during the following differentiation. At stage 40, characteristics like the strong 
hyperpigmentation, the bulge formation in the head and the truncated main body axis had 
almost normalized completely. The trunk bulges and the curvature of the main body axis 
became less prominent. At stage 40, eyes were visible but still retarded and/or malformed. 
Also characteristics such as the strongly reduced motor reaction to exogenous stimuli that 
was observed in earlier stages normalized completely up to stage 40.  This might suggest 
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that the alterations in differentiation are to a large degree reversible. A likely cause of such 
improvement would be the turnover of the injected RNA.  It was described previously that the 
majority of injected mRNAs is present up to stage 28, when phenotypic changes are most 
prominent, and has turned over by stage 40, when changes have partially normalized 
(Harland and Misher 1988; Gove, Walmsley et al. 1997). This decay of RNA might explain 
the transient nature of the observed phenotypic changes.  Therefore, Oct60 might induce a 
transient arrest in cell differentiation. This implicates that cells are able to undergo 
differentiation as soon as Oct60 expression ceases.  
 
 
5.5 Oct60 promotes neuroectodermal fate while repressing 
mesoderm formation 
5.5.1 Oct60 and its G.o.F. variants produce a broadened, non-organized n-ß-
tubulin expressing domain and disturb placode and eye formation 
 
To gain further insights into the molecular nature of the observed phenotypic changes, in situ 
hybridizations were performed with general markers for neuroectodermal, mesodermal and 
endodermal differentiation (Figure 17, 18).  
No changes were found in the expression of the endodermal marker endodermin (data not 
shown). Expression levels of the neural marker n-ß-tubulin and the mesodermal markers 
xbra and cardiac actin were strongly altered by injection of oct60 and its G.o.F. variants. 
 
In situ hybridization with the late neural marker n-ß-tubulin revealed a broadening of the n-ß-
tubulin expressing domain on the injected side of oct60, enR-oct60 as well as vp16-oct60 
injected embryos. N-ß-tubulin expressing cells were detectable at almost the whole 
broadened head region. Development of eyes and placodes was strongly inhibited. Placodes 
were not detectable on the injected side in most cases. Interestingly, Oct60 and its G.o.F. 
variants produced similar ectopic n-ß-tubulin expressing domains. Broadening of the n-ß-
tubulin domain was most prominent in vp16-oct60 injected embryos. Taken together, it 
appears that neural n-ß-tubulin expressing cells are being formed but not organized in a 
proper manner.   
The fact that n-ß-tubulin seems to be upregulated in the head region by all injected oct60 
constructs was surprising. Though changes observed within the head region displayed 
similarities between the injected constructs, differences were observed within the trunk 
region. Ectopic expression of n-ß-tubulin was observed within the anterior trunk region 
mainly in enR-oct60 injected embryos. N-ß-tubulin did not stain the trunk bulges observed in 
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enR-oct60 injected embryos. N-ß-tubulin expressing cells that are usually equally spread 
over the whole trunk region spared the region of the trunk outgrowth. In contrast, lacZ 
positive cells were highly concentrated within these bulges. Possible explanations include 
cell migration to the region of bulge formation, or a higher rate of cell proliferation in this area. 
High cell proliferation rates are also found during embryonic development and in neoplastic 
lesions. Interestingly, Oct4 is known to be involved in both processes. Multiple tumors were 
found to express Oct4 protein (Atlasi, Mowla et al. 2007; Chen, Hsu et al. 2008; Wang, Meng 
et al. 2010). Whether the observed bulges display a tumor-like lesion remains uncertain. 
 
5.5.2 Oct60 and its G.o.F. variants inhibit the expression of early and late 
mesodermal markers  
Strong downregulation of xbra and cardiac actin expression was observed in embryos 
overexpressing Oct60 and its G.o.F. variants (Figure 18). Therefore, Xenopus Oct60 and its 
G.o.F variants all direct cell differentiation in a similar manner. They are promoting 
neuroectodermal fate, while repressing mesodermal differentiation. This result was surprising 
because it cannot be explained by transcriptional regulation. Both direct as well as an indirect 
transcriptional regulation should produce regulatory effects in opposite directions.  
One possible explanation might be that regulation does not occur on the level of 
transcription. First evidence that Oct proteins can influence protein levels on a post-
transcriptional level came from recently published data suggesting that mouse Oct4 forms a 
physical complex with ß-catenin in the nucleus. Thus, Oct4 facilitates proteasomal 
degradation of ß-catenin. The same effect was also described for Xenopus Oct25 (Abu-
Remaileh, Gerson et al. 2010). Regulatory effects on a post-transcriptional level could 
explain similarities observed in the regulation of mesodermal and neural markers between 
Oct60 and its G.o.F. variants. The neomorphic protein variants are only able to fulfill their 
additional activating and repressing functions, if regulation occurs on a transcriptional level 
as it was demonstrated in the luciferase assay. In this case differences between the G.o.F. 
variants should be detectable. Effector domains will not fulfill their functions, if proteins are 
regulated post-transcriptionally. This could explain that there is no inverse regulation of 
mesodermal and neuroectodermal markers by Oct60 G.o.F. variants.  
Our G.o.F. variants represent interesting tools for the further analysis of regulatory pathways 
controlled by Xenopus Oct proteins. By comparing regulatory effects of activating and 
repressing transcription factor variants, it might be possible to differentiate between 
transcriptional and non-transcriptional regulation. 
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5.6 Does Oct60 and its G.o.F. variants produce tumor-like 
lesions in Xenopus embryos? 
The molecular nature of the bulges observed in the trunk region, the hyperpigmentation and 
the broadening of the head domain remain unexplained. Further studies are being performed 
to clarify these questions. One similarity between the observed phenotypic changes is that all 
of them possess features of dysplastic growth: high amounts of lacZ expressing cells were 
found in the trunk outgrowth of enR-oct60 injected embryos that might reflect a high cell 
proliferation rate. The same process could possibly explain proliferation of melanin producing 
cells and n-ß-tubulin expressing cells in the head region. Tumors produced by ectopic 
expression of Oct4 were shown to be dependent on Oct4 expression and were fully 
reversible when Oct4 expression was ceased (Hochedlinger, Yamada et al. 2005). Similar to 
this, phenotypic changes observed by overexpression of Oct60 and its G.o.F. variants were 
transient to various degrees. Hyperpigmentation defects vanished almost completely in most 
cases by stage 40, showing its maximum around stage 26. Also bulges in the trunk region 
and the broadening of the head domain disappeared partially by stage 40. This might 
indicate that phenotypic changes are dependent on the continuous expression of Oct60 and 
its G.o.F. variants and cease when synthetic mRNAs are degraded.  
 
 
5.7 Recent development in the field of Xenopus Oct research  
Among the Xenopus Oct proteins, the best-studied one is probably Oct25. The group of 
Walter Knöchel from the University of Ulm has done most of the work on the molecular 
functions of Oct25. Their work shows multiple similarities but also differences compared to 
my work. When comparing my results with theirs, one has to keep in mind, that their 
injections were targeted differently. While the group of Walter Knöchel examined phenotypic 
changes produced by ectopic expression of Oct protein within the vegetal region of the 
developing embryo, we injected oct60 and its G.o.F. variants into the animal hemisphere. 
Thereby, I attempted to interfere with Oct proteins within their normal territory of expression.  
 
Knöchel et al. were able to show that Oct25 binds to the Xvent2B promoter and stimulates 
transcription of the Xvent-2B gene. Thereby, overexpression of Oct25 leads to upregulation 
of BMP4 and Xvent genes (Cao, Knochel et al. 2004). Furthermore, Oct25 and Oct60 were 
shown to inhibit activin/nodal and FGF signaling pathways (Cao, Siegel et al. 2006).  
Interestingly, phenotypes observed by overexpression of Oct25 show multiple similarities 
compared to phenotypic changes observed by Oct60 and its G.o.F. variants: overexpression 
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of Oct25 resulted in gastrulation defects, truncation of the embryos, loss of head structures 
including brain and eyes, loss of somite structures and no extension of the tail.  Additionally, 
they observed an accumulation of darkly pigmented cells at the lateral or ventral sides of the 
embryos that resembles the one observed in enR-oct60 injected embryos (Cao, Knochel et 
al. 2004). Similar to our results they demonstrated downregulation of the mesodermal 
markers xbra and cardiac actin (Cao, Knochel et al. 2004). In animal caps, injected with 
oct25, they observed an upregulation of the neuroectodermal genes sox2, sox3, geminin and 
zic1 but no expression of the differentiated primary neuron specific n-ß-tubulin gene at stage 
26. These findings indicate that Oct25 promotes neural fate by upregulating early 
neuroectodermal genes but suppresses terminal differentiation of neurons (Cao, Siegel et al. 
2006). Is this function of Oct25 different to the influences of Oct60 on neuroectodermal 
differentiation we observed? In situ hybridization on embryos stage 28 that were injected with 
oct60 and its G.o.F. variants showed a broadening of the n-ß-tubulin expressing domain with 
no visible eye structures and placodes. Though differences in functions seem to be evident 
between Oct25 and Oct60 at first glance, the findings might be conformable with a common 
role in neuroectodermal regulation. Differentiation might be prevented during early stages 
when Oct proteins are upregulated. An inappropriate differentiation might occur later, 
resulting in the observed broadened n-ß-tubulin expressing domain. It will be interesting to 
compare the expression of n-ß-tubulin during early development between control embryos 
and embryos injected with Oct proteins to determine, whether expression of n-ß-tubulin starts 
asynchronous. 
Downregulation of the endodermal marker sox17 by injection of oct25, oct60 and oct91 was 
described by the group of Walter Knöchel (Cao, Siegel et al. 2006). Our experiments showed 
no alteration in the expression of the late endodermal marker endodermin. Whether these 
differences result from the different mode of injection or different endodermal markers 
examined remains uncertain.  
More recent studies of Knöchel et al. showed that Oct25 inhibits the expression of VegT and 
ß-Catenin target genes through complex formation. VegT and ß-Catenin are both expressed 
in the vegetal half of the developing embryo and are thought to play a key role in mesoderm 
induction by activating transcription of Xnrs (Cao, Siegel et al. 2007). 
Interestingly, similar to our results, both, dominant activating as well as repressing fusion 
proteins of Oct25 produced a downregulation of the mesodermal marker xbra (Cao, Siegel et 
al. 2008). Whether this unidirectional regulation is due to post-transcriptional regulation, as 
mentioned above, remain to be evaluated. 
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5.8 Outlook 
Future studies will attempt to identify the molecular mechanisms underlying the observed 
phenotypic changes. It will be particularly interesting to investigate the fate of the trunk 
bulges as well as the head defects with regards to neoplastic growth. Therefore, molecular 
studies including in situ hybridizations and RT-PCR have to be performed. Hereby, animal 
cap assays might serve as additional in vitro models. Furthermore, the Rupp laboratory is 
planning to perform cross sections for pathological assessment.  
 
At present, Oct60 knockdown experiments, performed by injection of morpholino 
oligonucleotides, are being carried out in our lab. Comparison of knockdown and 
overexpression phenotypes will provide further information on the activating and repressing 
functions of Oct60. Recently published data suggests that Oct proteins are able to regulate 
protein expression at the post-transcriptional level (Abu-Remaileh, Gerson et al. 2010). Non-
transcriptional regulation might explain the unidirectional regulation of various differentiation 
markers observed in in situ hybridizations. Further studies should attempt to evaluate the 
level of protein regulation that is responsible for the observed molecular changes.  
 
Furthermore, dominant activating and repressing protein variants of Oct25 and Oct91 have 
been cloned. Comparison of the three Xenopus Oct4 homologs will be interesting to find out 
to which degree they share redundant functions.  
 
Due to time limitations we could not perform experiments using the GR-fusion constructs. 
These constructs are important tools to further analyze Xenopus Oct protein function. Like 
mammalian Oct4, Xenopus Oct4 homologs are mainly expressed in early development. 
Recent experiments performed in mice and human fibroblasts suggest that Oct4 is sufficient 
to reprogram differentiated cells (Takahashi and Yamanaka 2006; Okita, Ichisaka et al. 2007; 
Takahashi, Tanabe et al. 2007). Additionally, Oct4 expression was detected in several 
neoplastic lesions such as lung cancer, bladder cancer and breast cancer (Atlasi, Mowla et 
al. 2007; Chen, Hsu et al. 2008; Wang, Meng et al. 2010). These findings suggest that 
differentiated cells are still reactive to mammalian Oct protein expression. Thus, it will be 
interesting to examine the effects of de novo Xenopus Oct protein expression later in 
development using the generated GR-fusion constructs.  
 
To conclude, it should be pointed out that the unutilized Oct25, Oct91 as well as GR-
constructs represent important tools with untapped potential. Their use will hopefully 
contribute to the resolution of further unanswered questions concerning Oct protein function.
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6 Abbreviations 
 
bp  base pairs 
cDNA  complementary DNA 
DEPC  diethlypryocarbonate 
ddH2O  double-distilled water 
DNA  deoxyribonucleic acid 
e.g.  exempli gratia, for example 
et al.  et alii, and others 
etc.  et cetera 
g  gram 
GFP  green fluorescent protein 
G.o.F.             gain of function 
GST  glutathione S-transferase 
h  hour 
hpf hours post fertilization 
IP  immunoprecipitation 
l  liter 
kDa  kilodaltons 
min minutes 
M molar 
MBT mid-blastula transition 
ml milliliter 
mM millimolar 
mRNA messenger ribonucleic acid 
NF Xenopus developmental stages according to the normal table of staging of 
Xenopus laevis (Daudin) after (Niewkoop and Faber 1994) 
ng nanogram 
nm  nanometer 
NTPs nucleotide triphosphate mixture containing adenosine, guanidine, uridine and 
cytosine 
PCR  polymerase chain reaction 
pg                   picogram 
pg/E                picogram per embryo 
pmol  picomol 
RNA  ribonucleic acid 
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rpm  revolutions per minute 
RT  room temperature 
RT-PCR reverse transcription polymerase chain reaction 
SDS  sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gelelectrophoresis 
sec  seconds 
WB  Western blot analysis 
µg  microgram 
µl  microliter 
µM  micromolar 
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